Overview

Our principal business is owning and operating, through our subsidiaries, acute care hospitals and outpatient facilities and behavioral health care facilities.



As of September 30, 2021, we owned and/or operated 360 inpatient facilities and
40 outpatient and other facilities including the following located in 38 U.S
states, Washington, D.C., the United Kingdom and Puerto Rico:

Acute care facilities located in the U.S.:



  • 27 inpatient acute care hospitals;


  • 18 free-standing emergency departments, and;


  • 6 outpatient centers & 1 surgical hospital.

Behavioral health care facilities (333 inpatient facilities and 15 outpatient facilities):



Located in the U.S.:

  • 185 inpatient behavioral health care facilities, and;


  • 12 outpatient behavioral health care facilities.

Located in the U.K.:



  • 145 inpatient behavioral health care facilities, and;


  • 3 outpatient behavioral health care facilities.

Located in Puerto Rico:

• 3 inpatient behavioral health care facilities.




As a percentage of our consolidated net revenues, net revenues from our acute
care hospitals, outpatient facilities and commercial health insurer accounted
for 58% and 55% during the three-month periods ended September 30, 2021 and
2020, respectively, and 56% and 54% during the nine-month periods ended
September 30, 2021 and 2020, respectively. Net revenues from our behavioral
health care facilities and commercial health insurer accounted for 42% and 45%
of our consolidated net revenues during the three-month periods ended September
30, 2021 and 2020, respectively, and 44% and 46% during the nine-month periods
ended September 30, 2021 and 2020, respectively.

Our behavioral health care facilities located in the U.K. generated net revenues
of approximately $174 million and $155 million during the three-month periods
ended September 30, 2021 and 2020, respectively, and $511 million and $429
million during the nine-month periods ended September 30, 2021 and 2020,
respectively. Total assets at our U.K. behavioral health care facilities were
approximately $1.338 billion as of September 30, 2021 and $1.334 billion as of
December 31, 2020.

Services provided by our hospitals include general and specialty surgery,
internal medicine, obstetrics, emergency room care, radiology, oncology,
diagnostic care, coronary care, pediatric services, pharmacy services and/or
behavioral health services. We provide capital resources as well as a variety of
management services to our facilities, including central purchasing, information
services, finance and control systems, facilities planning, physician
recruitment services, administrative personnel management, marketing and public
relations.

Forward-Looking Statements and Risk Factors



You should carefully review the information contained in this Quarterly Report,
and should particularly consider any risk factors that we set forth in our
Annual Report on Form 10-K for the year ended December 31, 2020, this Quarterly
Report and in other reports or documents that we file from time to time with the
Securities and Exchange Commission (the "SEC"). In this Quarterly Report, we
state our beliefs of future events and of our future financial performance. This
Quarterly Report contains "forward-looking statements" that reflect our current
estimates, expectations and projections about our future results, performance,
prospects and opportunities. Forward-looking statements include, among other
things, the information concerning our possible future results of operations,
business and growth strategies, financing plans, expectations that regulatory
developments or other matters will not have a material adverse effect on our
business or financial condition, our competitive position and the effects of
competition, the projected growth of the industry in which we operate, and the
benefits and synergies to be obtained from our completed and any future
acquisitions, and statements of our goals and objectives, and other similar
expressions concerning matters that are not historical facts. Words such as
"may," "will," "should," "could," "would," "predicts," "potential," "continue,"
"expects," "anticipates," "future," "intends," "plans," "believes," "estimates,"
"appears," "projects" and similar expressions, as well as statements in future
tense, identify forward-looking statements. In evaluating those statements, you
should specifically consider various factors, including the risks related to
healthcare industry trends and those set forth in Item 1A. Risk Factors and Item
7. Management's Discussion and Analysis of Financial Condition and Results of
Operations-Forward Looking Statements and Risk Factors in our Annual Report on
Form 10-K for the year ended

                                       26

--------------------------------------------------------------------------------

December 31, 2020 ("Form 10-K") and in Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations-Forward Looking Statements and Risk Factors, as included herein.



Forward-looking statements should not be read as a guarantee of future
performance or results, and will not necessarily be accurate indications of the
times at, or by which, such performance or results will be achieved.
Forward-looking information is based on information available at the time and/or
our good faith belief with respect to future events, and is subject to risks and
uncertainties that could cause actual performance or results to differ
materially from those expressed in the statements. Such factors include, among
other things, the following:



    •   we are subject to risks associated with public health threats and
        epidemics, including the health concerns relating to the COVID-19

pandemic. In January 2020, the Centers for Disease Control and Prevention

("CDC") confirmed the spread of the disease to the United States. In

March 2020, the World Health Organization declared the COVID-19 outbreak a


        pandemic. The federal government has declared COVID-19 a national
        emergency, as many federal and state authorities have implemented
        aggressive measures to "flatten the curve" of confirmed individuals
        diagnosed with COVID-19 in an attempt to curtail the spread of the virus
        and to avoid overwhelming the health care system;

• the impact of the COVID-19 pandemic, which began during the second half of

March, 2020, has had a material effect on our operations and financial

results since that time. The COVID-19 vaccination process commenced during

the first quarter of 2021. Since that time through the second quarter of

2021, we had generally experienced a decline in COVID-19 patients as well

as a corresponding recovery in non-COVID patient activity. However, during

the third quarter of 2021, our facilities generally experienced an

increase in COVID-19 patients resulting primarily from the Delta variant.

Since the future volumes and severity of COVID-19 patients remain highly

uncertain and subject to change, including potential increases in future

COVID-19 patient volumes caused by new variants of the virus, as well as

related pressures on staffing and wage rates, we are not able to fully

quantify the impact that these factors will have on our future financial


        results. However, developments related to the COVID-19 pandemic could
        materially affect our financial performance during the remainder of 2021
        and into 2022. Even after the COVID-19 pandemic has subsided, we may
        continue to experience materially adverse impacts on our financial

condition and our results of operations as a result of its macroeconomic

impact, and many of our known risks described in the Risk Factors section


        of our Annual Report on Form 10-K for the year ended December 31, 2020;


    •   the Centers for Medicare and Medicaid Services ("CMS") issued an Interim

Final Rule ("IFR") effective November 5, 2021 mandating COVID-19

vaccinations for all applicable staff at all Medicare and Medicaid

certified facilities. Facilities covered by this regulation must establish

a policy ensuring all eligible staff have received the first dose of a

two-dose COVID-19 vaccine or a one-dose COVID-19 vaccine prior to

providing any care, treatment, or other services by December 5, 2021. All

eligible staff must have received the necessary shots to be fully

vaccinated - either two doses of Pfizer or Moderna or one dose of Johnson

& Johnson - by January 4, 2022. The regulation also provides for

exemptions based on recognized medical conditions or religious beliefs,

observances, or practices. Facilities must develop a similar process or

plan for permitting exemptions in alignment with federal law. If

facilities fail to comply with the IFR by the deadlines established, they


        are subject to potential termination from the Medicare and Medicaid
        program for non-compliance.  In addition, the Occupational Safety and
        Health Administration also issued an Emergency Temporary Standard

requiring all businesses with 100 or more employees to be vaccinated by

January 4, 2022. Those employees not vaccinated by that date will need to

show a negative COVID-19 test weekly and wear a face mask in the

workplace. However, healthcare employees at healthcare facilities covered

by the CMS IFR will not have the option of weekly COVID-19 testing in lieu

of vaccination. Legal challenges to these rules are expected and we cannot

predict at this time the potential viability or impact of such

litigation. Implementation of these rules could have an impact on

staffing at our facilities for those employees that are not vaccinated by

January 4, 2022, and associated loss of revenues and increased costs

resulting from staffing issues could have a material adverse effect on our

financial results;

• the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act"),

a stimulus package signed into law on March 27, 2020, authorizes $100

billion in grant funding to hospitals and other healthcare providers to be


        distributed through the Public Health and Social Services Emergency Fund
        (the "PHSSEF"). These funds are not required to be repaid provided the
        recipients attest to and comply with certain terms and conditions,
        including limitations on balance billing and not using PHSSEF funds to
        reimburse expenses or losses that other sources are obligated to

reimburse. However, since the expenses and losses will be ultimately

measured over the life of the COVID-19 pandemic, potential retrospective

unfavorable adjustments in future periods, of funds recorded as revenues


        in prior periods, could occur. The U.S. Department of Health and Human
        Services ("HHS") initially distributed $30 billion of this funding based

on each provider's share of total Medicare fee-for-service reimbursement

in 2019. Subsequently, HHS determined that CARES Act funding (including

the $30 billion already distributed) would be allocated proportional to

providers' share of 2018 net patient revenue. We have received payments


        from these initial distributions of the PHSSEF as disclosed herein. HHS
        has indicated that distributions of the remaining $50 billion will be
        targeted primarily to hospitals in COVID-19 high impact areas, to rural
        providers, safety net hospitals and certain Medicaid providers and to
        reimburse providers for COVID-19


                                       27

--------------------------------------------------------------------------------

related treatment of uninsured patients. We have received payments from

these targeted distributions of the PHSSEF, as disclosed herein. The CARES

Act also makes other forms of financial assistance available to healthcare

providers, including through Medicare and Medicaid payment adjustments and

an expansion of the Medicare Accelerated and Advance Payment Program,

which made available accelerated payments of Medicare funds in order to

increase cash flow to providers. On April 26, 2020, the Centers for

Medicare and Medicaid Services ("CMS") announced it was reevaluating and

temporarily suspending the Medicare Accelerated and Advance Payment

Program in light of the availability of the PHSSEF and the significant

funds available through other programs. We have received accelerated

payments under this program during 2020, and returned early all of those

funds during the first quarter of 2021, as disclosed herein. The Paycheck

Protection Program and Health Care Enhancement Act (the "PPPHCE Act"), a

stimulus package signed into law on April 24, 2020, includes additional

emergency appropriations for COVID-19 response, including $75 billion to

be distributed to eligible providers through the PHSSEF. A third phase of

PHSSEF allocations made $24.5 billion available for providers who

previously received, rejected or accepted PHSSEF payments. Applicants that

had not yet received PHSSEF payments of 2 percent of patient revenue were

to receive a payment that, when combined with prior payments (if any),

equals 2 percent of patient care revenue. Providers that have already


        received payments of approximately 2 percent of annual revenue from
        patient care were potentially eligible for an additional
        payment. Recipients will not be required to repay the government for
        PHSSEF funds received, provided they comply with HHS defined terms and
        conditions. On December 27, 2020, the Consolidated Appropriations Act,

2021 ("CAA") was signed into law. The CAA appropriated an additional $3

billion to the PHSSEF, codified flexibility for providers to calculate

lost revenues, and permitted parent organizations to allocate PHSSEF

targeted distributions to subsidiary organizations. The CAA also provides


        that not less than 85 percent of the unobligated PHSSEF amounts and any
        future funds recovered from health care providers should be used for
        additional distributions that consider financial losses and changes in
        operating expenses in the third or fourth quarters of 2020 and the first

quarter of 2021 that are attributable to the coronavirus. The CAA provided


        additional funding for testing, contact tracing and vaccine
        administration. Providers receiving payments were required to sign terms
        and conditions regarding utilization of the payments. Any provider

receiving funds in excess of $10,000 in the aggregate will be required to


        report data elements to HHS detailing utilization of the payments, and we
        will be required to file such reports. We, and other providers, will

report healthcare related expenses attributable to COVID-19 that have not

been reimbursed by another source, which may include general and

administrative or healthcare related operating expenses. Funds may also be

applied to lost revenues, represented as a negative change in

year-over-year net patient care operating income. The deadline for using

all Provider Relief Fund payments depends on the date of the payment

received period; payments received in the first period of April 10, 2020

to June 30, 2020 were to have been expended by June 30, 2021 and payments

received in the fourth period of July 1, 2021 to December 31, 2021 must be

expended by December 31, 2022. The American Rescue Plan Act of 2021

("ARPA"), enacted on March 11, 2021, included funding directed at

detecting, diagnosing, tracing, and monitoring COVID-19 infections;

establishing community vaccination centers and mobile vaccine units;

promoting, distributing, and tracking COVID-19 vaccines; and reimbursing

rural hospitals and facilities for healthcare-related expenses and lost

revenues attributable to COVID-19. ARPA increased the eligibility for, and

amount of, premium tax credits to purchase health coverage through Patient

Protection and Affordable Care Act, as amended by the Health and Education

Reconciliation Act (collectively, the "Legislation"). Further, ARPA set

the Medicaid program's federal medical assistance percentage ("FMAP") at


        100 percent for amounts expended for COVID-19 vaccines and vaccine
        administration. ARPA also increases the FMAP by 5 percent for eight
        calendar quarters to incentivize states to expand their Medicaid
        programs. Finally, ARPA provides subsidies to cover 100 percent of health

insurance premiums under the Consolidated Omnibus Budget Reconciliation

Act through September 30, 2021. There is a high degree of uncertainty

surrounding the implementation of the CARES Act, the PPPHCE Act, the CAA

and ARPA, and the federal government may consider additional stimulus and

relief efforts, but we are unable to predict whether additional stimulus


        measures will be enacted or their impact. There can be no assurance as to
        the total amount of financial and other types of assistance we will
        receive under the CARES Act, the PPPHCE Act, the CAA and the ARPA, and it

is difficult to predict the impact of such legislation on our operations


        or how they will affect operations of our competitors. Moreover, we are
        unable to assess the extent to which anticipated negative impacts on us

arising from the COVID-19 pandemic will be offset by amounts or benefits


        received or to be received under the CARES Act, the PPPHCE Act, the CAA
        and the ARPA;

• our ability to comply with the existing laws and government regulations,

and/or changes in laws and government regulations;

• an increasing number of legislative initiatives have been passed into law


        that may result in major changes in the health care delivery system on a
        national or state level. For example, Congress has reduced to $0 the
        penalty for failing to maintain health coverage that was part of the

original Legislation as part of the Tax Cuts and Jobs Act. President Biden

has undertaken and is expected to undertake additional executive actions

that will strengthen the Legislation and reverse the policies of the prior

administration. To date, the Biden administration has issued executive

orders implementing a special enrollment period permitting individuals to

enroll in health plans outside of the annual open enrollment period and

reexamining policies that may undermine the Legislation or the Medicaid

program. The ARPA's expansion of subsidies to purchase coverage through a

Legislation exchange is anticipated to increase exchange enrollment. The


        Trump


                                       28

--------------------------------------------------------------------------------

Administration had directed the issuance of final rules (i) enabling the

formation of association health plans that would be exempt from certain

Legislation requirements such as the provision of essential health

benefits, (ii) expanding the availability of short-term, limited duration

health insurance, (iii) eliminating cost-sharing reduction payments to

insurers that would otherwise offset deductibles and other out-of-pocket

expenses for health plan enrollees at or below 250 percent of the federal

poverty level, (iv) relaxing requirements for state innovation waivers

that could reduce enrollment in the individual and small group markets and

lead to additional enrollment in short-term, limited duration insurance

and association health plans and (v) incentivizing the use of health

reimbursement arrangements by employers to permit employees to purchase

health insurance in the individual market. The uncertainty resulting from


        these Executive Branch policies may have led to reduced Exchange
        enrollment in 2018, 2019 and 2020. It is also anticipated that these
        policies, to the extent that they remain as implemented, may create
        additional cost and reimbursement pressures on hospitals, including ours.
        In addition, there have been numerous political and legal efforts to

expand, repeal, replace or modify the Legislation since its enactment,

some of which have been successful, in part, in modifying the Legislation,

as well as court challenges to the constitutionality of the Legislation.

The U.S. Supreme Court rejected the latest such case on June 17, 2021,

when the Court held in California v. Texas that the plaintiffs lacked

standing to challenge the Legislation's requirement to obtain minimum

essential health insurance coverage, or the individual mandate. The Court

dismissed the case without specifically ruling on the constitutionality of

the Legislation. As a result, the Legislation will continue to remain law,

in its entirety, likely for the foreseeable future. Any future efforts to

challenge, replace or replace the Legislation or expand or substantially

amend its provision is unknown. See below in Sources of Revenue and Health

Care Reform for additional disclosure;

• under the Legislation, hospitals are required to make public a list of

their standard charges, and effective January 1, 2019, CMS has required

that this disclosure be in machine-readable format and include charges for

all hospital items and services and average charges for diagnosis-related

groups. On November 27, 2019, CMS published a final rule on "Price

Transparency Requirements for Hospitals to Make Standard Charges Public."

This rule took effect on January 1, 2021 and requires all hospitals to

also make public their payor-specific negotiated rates, minimum negotiated

rates, maximum negotiated rates, and cash for all items and services,


        including individual items and services and service packages, that could
        be provided by a hospital to a patient. Failure to comply with these
        requirements may result in daily monetary penalties. On November 2, 2021,

CMS released a final rule amending several hospital price transparency

policies and increasing the amount of penalties for noncompliance through

the use of a scaling factor based on hospital bed count;

• as part of the CAA, Congress passed legislation aimed at preventing or


        limiting patient balance billing in certain circumstances. The CAA
        addresses surprise medical bills stemming from emergency services,
        out-of-network ancillary providers at in-network facilities, and air
        ambulance carriers. The legislation prohibits surprise billing when
        out-of-network emergency services or out-of-network services at an

in-network facility are provided, unless informed consent is received. In

these circumstances providers are prohibited from billing the patient for

any amounts that exceed in-network cost-sharing requirements. On July 13,

2021, HHS, the Department of Labor and the Department of the Treasury

issued an interim final rule, which begins to implement the legislation.

The rule would limit our ability to receive payment for services at

usually higher out-of-network rates in certain circumstances and prohibit

out-of-network payments in other circumstances;

• possible unfavorable changes in the levels and terms of reimbursement for

our charges by third party payers or government based payers, including

Medicare or Medicaid in the United States, and government based payers in

the United Kingdom;

• our ability to enter into managed care provider agreements on acceptable

terms and the ability of our competitors to do the same;

• the outcome of known and unknown litigation, government investigations,

false claims act allegations, and liabilities and other claims asserted

against us and other matters as disclosed in Note 6 to the Consolidated

Financial Statements - Commitments and Contingencies and the effects of

adverse publicity relating to such matters;

• the unfavorable impact on our business of the deterioration in national,

regional and local economic and business conditions, including a worsening

of unfavorable credit market conditions;

• competition from other healthcare providers (including physician owned

facilities) in certain markets;

• technological and pharmaceutical improvements that increase the cost of

providing, or reduce the demand for healthcare;

• our ability to attract and retain qualified personnel, nurses, physicians

and other healthcare professionals and the impact on our labor expenses

resulting from a shortage of nurses and other healthcare professionals;




  • demographic changes;

• we experienced a cyberattack in September, 2020 that had an adverse effect

on our operating results during the fourth quarter of 2020. Although we


        can provide no assurance or estimation related to the amount of the
        ultimate insurance


                                       29

--------------------------------------------------------------------------------

proceeds that we may receive in connection with this incident ($20 million

of insurance proceeds have been received to date), we believe we are

entitled to recovery of the majority of the unfavorable economic impact of

the cyberattack pursuant to a commercial insurance policy. However, there

is a heightened risk of future cybersecurity threats, including ransomware

attacks targeting healthcare providers. If successful, future cyberattacks

could have a material adverse effect on our business. Any costs that we

incur as a result of a data security incident or breach, including costs

to update our security protocols to mitigate such an incident or breach

could be significant. Any breach or failure in our operational security

systems can result in loss of data or an unauthorized disclosure of or

access to sensitive or confidential member or protected personal or health


        information and could result in significant penalties or fines,
        litigation, loss of customers, significant damage to our reputation and
        business, and other losses;

• the availability of suitable acquisition and divestiture opportunities and

our ability to successfully integrate and improve our acquisitions since

failure to achieve expected acquisition benefits from certain of our prior

or future acquisitions could result in impairment charges for goodwill and


        purchased intangibles;


    •   the impact of severe weather conditions, including the effects of
        hurricanes and climate change;

• as discussed below in Sources of Revenue, we receive revenues from various

state and county based programs, including Medicaid in all the states in

which we operate (we receive Medicaid revenues in excess of $100 million

annually from each of California, Texas, Nevada, Washington, D.C.,

Pennsylvania, Illinois, Kentucky and Massachusetts); CMS-approved Medicaid

supplemental programs in certain states including Texas, Mississippi,

Illinois, Oklahoma, Nevada, Arkansas, California and Indiana, and; state


        Medicaid disproportionate share hospital payments in certain states
        including Texas and South Carolina. We are therefore particularly
        sensitive to potential reductions in Medicaid and other state based
        revenue programs as well as regulatory, economic, environmental and

competitive changes in those states. We can provide no assurance that

reductions to revenues earned pursuant to these programs, and the effect


        of the COVID-19 pandemic on state budgets, particularly in the
        above-mentioned states, will not have a material adverse effect on our
        future results of operations;

• our ability to continue to obtain capital on acceptable terms, including

borrowed funds, to fund the future growth of our business;

• our inpatient acute care and behavioral health care facilities may

experience decreasing admission and length of stay trends;

• our financial statements reflect large amounts due from various commercial

and private payers and there can be no assurance that failure of the

payers to remit amounts due to us will not have a material adverse effect

on our future results of operations;

• the Budget Control Act of 2011 (the "2011 Act") imposed annual spending


        limits for most federal agencies and programs aimed at reducing budget
        deficits by $917 billion between 2012 and 2021, according to a report

released by the Congressional Budget Office. Among its other provisions,

the law established a bipartisan Congressional committee, known as the

Joint Select Committee on Deficit Reduction (the "Joint Committee"), which

was tasked with making recommendations aimed at reducing future federal


        budget deficits by an additional $1.5 trillion over 10 years. The Joint
        Committee was unable to reach an agreement by the November 23, 2011
        deadline and, as a result, across-the-board cuts to discretionary,
        national defense and Medicare spending were implemented on March 1, 2013

resulting in Medicare payment reductions of up to 2% per fiscal year with

a uniform percentage reduction across all Medicare programs. The

Bipartisan Budget Act of 2015, enacted on November 2, 2015, continued the

2% reductions to Medicare reimbursement imposed under the 2011 Act. Recent

legislation has suspended payment reductions through December 31, 2021 in

exchange for extended cuts through 2030. We cannot predict whether

Congress will restructure the implemented Medicare payment reductions or

what other federal budget deficit reduction initiatives may be proposed by

Congress going forward. See below in 2019 Novel Coronavirus Disease

Medicare and Medicaid Payment Related Legislation - Medicare Sequestration


        Relief, for additional disclosure related to the favorable effect the
        legislative extensions have had/are expected to have on our results of
        operations during 2020 and 2021;

• uninsured and self-pay patients treated at our acute care facilities


        unfavorably impact our ability to satisfactorily and timely collect our
        self-pay patient accounts;


  • changes in our business strategies or development plans;


• in June, 2016, the United Kingdom affirmatively voted in a non-binding

referendum in favor of the exit of the United Kingdom ("U.K.") from the

European Union (the "Brexit") and it was approved by vote of the British

legislature. On March 29, 2017, the United Kingdom triggered Article 50 of

the Lisbon Treaty, formally starting negotiations regarding its exit from

the European Union. On January 31, 2020, the U.K. formally exited the

European Union. On December 24, 2020, the United Kingdom and the European

Union reached a post-Brexit trade and cooperation agreement that created

new business and security requirements and preserved the United Kingdom's


        tariff- and quota-free access to the European


                                       30

--------------------------------------------------------------------------------

Union member states. We do not know to what extent Brexit will ultimately

impact the business and regulatory environment in the U.K., the European

Union, or other countries. Any of these effects of Brexit, and others we


        cannot anticipate, could harm our business, financial condition and
        results of operations, and;


    •   other factors referenced herein or in our other filings with the
        Securities and Exchange Commission.


Given these uncertainties, risks and assumptions, as outlined above, you are
cautioned not to place undue reliance on such forward-looking statements. Our
actual results and financial condition could differ materially from those
expressed in, or implied by, the forward-looking statements. Forward-looking
statements speak only as of the date the statements are made. We assume no
obligation to publicly update any forward-looking statements to reflect actual
results, changes in assumptions or changes in other factors affecting
forward-looking information, except as may be required by law. All
forward-looking statements attributable to us or persons acting on our behalf
are expressly qualified in their entirety by this cautionary statement.

Critical Accounting Policies and Estimates



The preparation of financial statements in conformity with accounting principles
generally accepted in the United States requires us to make estimates and
assumptions that affect the amounts reported in our consolidated financial
statements and accompanying notes. For a summary of our significant accounting
policies, please see Note 1 to the Consolidated Financial Statements as included
in our Annual Report on Form 10-K for the year ended December 31, 2020. We
consider our critical accounting policies to be those that require us to make
significant judgments and estimates when we prepare our financial statements,
including the following:

Revenue Recognition:  On January 1, 2018, we adopted, using the modified
retrospective approach, ASU 2014-09 and ASU 2016-08, "Revenue from Contracts
with Customers (Topic 606)" and "Revenue from Contracts with Customers:
Principal versus Agent Considerations (Reporting Revenue Gross versus Net)",
respectively, which provides guidance for revenue recognition. The standard's
core principle is that a company will recognize revenue when it transfers
promised goods or services to customers in an amount that reflects the
consideration to which the company expects to be entitled in exchange for those
goods or services. The most significant change from the adoption of the new
standard relates to our estimation for the allowance for doubtful accounts.
Under the previous standards, our estimate for amounts not expected to be
collected based upon our historical experience, were reflected as provision for
doubtful accounts, included within net revenue. Under the new standard, our
estimate for amounts not expected to be collected based on historical experience
will continue to be recognized as a reduction to net revenue, however, not
reflected separately as provision for doubtful accounts. Under the new standard,
subsequent changes in estimate of collectability due to a change in the
financial status of a payer, for example a bankruptcy, will be recognized as bad
debt expense in operating charges. The adoption of this ASU in 2018, and amounts
recognized as bad debt expense and included in other operating expenses, did not
have a material impact on our consolidated financial statements.

See Note 12 to the Consolidated Financial Statements-Revenue Recognition, for
additional disclosure related to our revenues including a disaggregation of our
consolidated net revenues by major source for each of the periods presented
herein.

Charity Care, Uninsured Discounts and Other Adjustments to Revenue:  Collection
of receivables from third-party payers and patients is our primary source of
cash and is critical to our operating performance. Our primary collection risks
relate to uninsured patients and the portion of the bill which is the patient's
responsibility, primarily co-payments and deductibles. We estimate our revenue
adjustments for implicit price concessions based on general factors such as
payer mix, the aging of the receivables and historical collection experience. We
routinely review accounts receivable balances in conjunction with these factors
and other economic conditions which might ultimately affect the collectability
of the patient accounts and make adjustments to our allowances as warranted. At
our acute care hospitals, third party liability accounts are pursued until all
payment and adjustments are posted to the patient account. For those accounts
with a patient balance after third party liability is finalized or accounts for
uninsured patients, the patient receives statements and collection letters.

Historically, a significant portion of the patients treated throughout our
portfolio of acute care hospitals are uninsured patients which, in part, has
resulted from patients who are employed but do not have health insurance or who
have policies with relatively high deductibles. Patients treated at our
hospitals for non-elective services, who have gross income of various amounts,
dependent upon the state, ranging from 200% to 400% of the federal poverty
guidelines, are deemed eligible for charity care. The federal poverty guidelines
are established by the federal government and are based on income and family
size. Because we do not pursue collection of amounts that qualify as charity
care, the transaction price is fully adjusted and there is no impact in our net
revenues or in our accounts receivable, net.

A portion of the accounts receivable at our acute care facilities are comprised
of Medicaid accounts that are pending approval from third-party payers but we
also have smaller amounts due from other miscellaneous payers such as county
indigent programs in certain states. Our patient registration process includes
an interview of the patient or the patient's responsible party at the time of
registration. At that time, an insurance eligibility determination is made and
an insurance plan code is assigned. There are various pre-established insurance
profiles in our patient accounting system which determine the expected insurance
reimbursement for each patient based on the insurance plan code assigned and the
services rendered. Certain patients may be classified as Medicaid pending at
registration

                                       31

--------------------------------------------------------------------------------


based upon a screening evaluation if we are unable to definitively determine if
they are currently Medicaid eligible. When a patient is registered as
Medicaid-eligible or Medicaid-pending, our patient accounting system records net
revenues for services provided to that patient based upon the established
Medicaid reimbursement rates, subject to the ultimate disposition of the
patient's Medicaid eligibility. When the patient's ultimate eligibility is
determined, reclassifications may occur which impacts net revenues in future
periods. Although the patient's ultimate eligibility determination may result in
adjustments to net revenues, these adjustments did not have a material impact on
our results of operations during the three and nine-month periods ended
September 30, 2021 or 2020 since our facilities make estimates at each financial
reporting period to adjust revenue based on historical collections.

We also provide discounts to uninsured patients (included in "uninsured
discounts" amounts below) who do not qualify for Medicaid or charity
care. Because we do not pursue collection of amounts classified as uninsured
discounts, the transaction price is fully adjusted and there is no impact in our
net revenues or in our net accounts receivable. In implementing the discount
policy, we first attempt to qualify uninsured patients for governmental
programs, charity care or any other discount program. If an uninsured patient
does not qualify for these programs, the uninsured discount is applied.

The following tables show the amounts recorded at our acute care hospitals for
charity care and uninsured discounts, based on charges at established rates, for
the three and nine-month periods ended September 30, 2021 and 2020:

Uncompensated care:

Amounts in millions                                Three Months Ended                                              Nine Months Ended
                                  September 30,                 September 30,                 September 30,                    September 30,
                                        2021           %              2020           %              2021            %                2020            %
Charity care                     $           189        33 %   $           148        27 %   $           535           35 %   $           511           30 %
Uninsured discounts                          378        67 %               410        73 %               987           65 %             1,221           70 %
Total uncompensated care         $           567       100 %   $           558       100 %   $         1,522          100 %   $         1,732          100 %


Estimated cost of providing uncompensated care:



The estimated costs of providing uncompensated care as reflected below were
based on a calculation which multiplied the percentage of operating expenses for
our acute care hospitals to gross charges for those hospitals by the
above-mentioned total uncompensated care amounts. The percentage of cost to
gross charges is calculated based on the total operating expenses for our acute
care facilities divided by gross patient service revenue for those facilities.



                                                 Three Months Ended                          Nine Months Ended
                                       September 30,           September 30,        September 30,          September 30,
Amounts in millions                           2021                    2020                 2021                  2020
Estimated cost of providing charity
care                                  $             20       $              17     $             57       $            60
Estimated cost of providing
uninsured discounts related care                    41                      47                  107                   142
Estimated cost of providing
uncompensated care                    $             61       $              64     $            164       $           202


Self-Insured/Other Insurance Risks: We provide for self-insured risks including
general and professional liability claims, workers' compensation claims and
healthcare and dental claims. Our estimated liability for self-insured
professional and general liability claims is based on a number of factors
including, among other things, the number of asserted claims and reported
incidents, estimates of losses for these claims based on recent and historical
settlement amounts, estimate of incurred but not reported claims based on
historical experience, and estimates of amounts recoverable under our commercial
insurance policies. All relevant information, including our own historical
experience is used in estimating the expected amount of claims. While we
continuously monitor these factors, our ultimate liability for professional and
general liability claims could change materially from our current estimates due
to inherent uncertainties involved in making this estimate. Our estimated
self-insured reserves are reviewed and changed, if necessary, at each reporting
date and changes are recognized currently as additional expense or as a
reduction of expense. In addition, we also: (i) own commercial health insurers
headquartered in Reno, Nevada, and Puerto Rico and; (ii) maintain self-insured
employee benefits programs for employee healthcare and dental claims. The
ultimate costs related to these programs/operations include expenses for claims
incurred and paid in addition to an accrual for the estimated expenses incurred
in connection with claims incurred but not yet reported. Given our significant
insurance-related exposure, there can be no assurance that a sharp increase in
the number and/or severity of claims asserted against us will not have a
material adverse effect on our future results of operations.

See Note 6 to the Consolidated Financial Statements-Commitments and Contingencies, for additional disclosure related to our professional and general liability, workers' compensation liability and property insurance.



The total accrual for our professional and general liability claims and workers'
compensation claims was $450 million as of September 30, 2021, of which $129
million is included in current liabilities. The total accrual for our
professional and general liability

                                       32

--------------------------------------------------------------------------------

claims and workers' compensation claims was $369 million as of December 31, 2020, of which $129 million is included in current liabilities.

Recent Accounting Standards: For a summary of accounting standards, please see Note 14 to the Consolidated Financial Statements, as included herein.



Results of Operations



COVID-19

The impact of the COVID-19 pandemic, which began during the second half of
March, 2020, has had a material effect on our operations and financial results
since that time. The COVID-19 vaccination process commenced during the first
quarter of 2021. Since that time, through the second quarter of 2021, we had
generally experienced a decline in COVID-19 patients as well as a corresponding
recovery in non-COVID-19 patient activity. However, during the third quarter of
2021, our facilities generally experienced an increase in COVID-19 patients
resulting primarily from the Delta variant. Since the future volumes and
severity of COVID-19 patients remain highly uncertain and subject to change,
including potential increases in future COVID-19 patient volumes caused by new
variants of the virus, as well as related pressures on staffing and wage rates,
we are not able to fully quantify the impact that these factors will have on our
future financial results. However, developments related to the COVID-19 pandemic
could materially affect our financial performance during the remainder of 2021
and into 2022.


2021 CARES Act Grants and Medicare Accelerated Payments Receipts/Disbursements:



During 2021, we received approximately $189 million of additional funds from the
federal government in connection with the CARES Act, substantially all of which
was received during the first quarter of 2021. During the second quarter of
2021, we returned the $189 million to the appropriate government agencies
utilizing a portion of our cash and cash equivalents held on deposit. Therefore,
our results of operations for the three and nine-month periods ended September
30, 2021 include no impact from the receipt of those funds.



Also, and as previously announced earlier this year, in March of 2021 we made an
early repayment of $695 million of funds received during 2020 pursuant to the
Medicare Accelerated and Advance Payment Program. These funds were returned to
the government utilizing a portion of our cash and cash equivalents held on
deposit.

Please see Sources of Revenue- 2019 Novel Coronavirus Disease Medicare and
Medicaid Payment Related Legislation below for additional disclosure regarding
funds received and related recognition of revenues in our results of operations
in connection with various governmental stimulus grant programs, most notably
the CARES Act.

Financial results for the three-month periods ended September 30, 2021 and 2020:

The following table summarizes our results of operations and is used in the discussion below for the three-month periods ended September 30, 2021 and 2020 (dollar amounts in thousands):



                                                Three months ended             Three months ended
                                                September 30, 2021             September 30, 2020
                                                             % of Net                       % of Net
                                              Amount         Revenues        Amount         Revenues
Net revenues                                $ 3,155,999          100.0 %   $ 2,912,541          100.0 %
Operating charges:
Salaries, wages and benefits                  1,556,448           49.3 %     1,406,348           48.3 %
Other operating expenses                        754,072           23.9 %       666,665           22.9 %
Supplies expense                                367,834           11.7 %       335,409           11.5 %
Depreciation and amortization                   134,462            4.3 %       125,961            4.3 %
Lease and rental expense                         28,375            0.9 %        28,488            1.0 %
Subtotal-operating expenses                   2,841,191           90.0 %     2,562,871           88.0 %
Income from operations                          314,808           10.0 %       349,670           12.0 %
Interest expense, net                            21,199            0.7 %        24,575            0.8 %
Other (income) expense, net                       6,719            0.2 %         1,831            0.1 %
Income before income taxes                      286,890            9.1 %       323,264           11.1 %
Provision for income taxes                       67,515            2.1 %        79,172            2.7 %
Net income                                      219,375            7.0 %       244,092            8.4 %
Less: Income attributable to
noncontrolling interests                          1,024            0.0 %         2,813            0.1 %
Net income attributable to UHS              $   218,351            6.9 %   $   241,279            8.3 %


                                       33

--------------------------------------------------------------------------------




Net revenues increased 8.4%, or $243 million, to $3.16 billion during the
three-month period ended September 30, 2021 as compared to $2.91 billion during
the third quarter of 2020. The net increase was primarily attributable to: (i) a
$234 million or 8.2% increase in net revenues generated from our acute care
hospital services and behavioral health services operated during both periods
(which we refer to as "same facility"), and; (ii) $9 million of other combined
net increases.

Income before income taxes (before deduction for income attributable to noncontrolling interests) decreased $36 million to $287 million during the three-month period ended September 30, 2021 as compared to $323 million during the comparable quarter of 2020. The $36 million net decrease was due to:

• an increase of $31 million at our acute care facilities, as discussed below

in Acute Care Hospital Services;

• a decrease of $55 million at our behavioral health care facilities, as


      discussed below in Behavioral Health Services, and;


  • $12 million of other combined net decreases.


Net income attributable to UHS decreased $23 million to $218 million during the
three-month period ended September 30, 2021 as compared to $241 million during
the comparable prior year quarter. This decrease was attributable to:

• a $36 million decrease in income before income taxes, as discussed above;

• an increase of $2 million due to a decrease in income attributable to

noncontrolling interests, and;

• an increase of $12 million resulting from a decrease in the provision for

income taxes due primarily to: (i) the income tax benefit recorded in

connection with the $38 million decrease in pre-tax income, partially offset

by; (ii) a $3 million decrease in the provision for income taxes resulting

from ASU 2016-09, "Compensation - Stock Compensation (Topic 718):

Improvements to Employee Share-Based Payment Accounting" ("ASU 2016-09").

Financial results for the nine-month periods ended September 30, 2021 and 2020:

The following table summarizes our results of operations and is used in the discussion below for the nine-month periods ended September 30, 2021 and 2020 (dollar amounts in thousands):



                                               Nine months ended               Nine months ended
                                               September 30, 2021              September 30, 2020
                                                            % of Net                        % of Net
                                             Amount         Revenues         Amount         Revenues
Net revenues                               $ 9,366,866          100.0 %    $ 8,471,962          100.0 %
Operating charges:
Salaries, wages and benefits                 4,542,156           48.5 %      4,147,027           49.0 %
Other operating expenses                     2,233,590           23.8 %      1,982,202           23.4 %
Supplies expense                             1,052,977           11.2 %        936,808           11.1 %
Depreciation and amortization                  399,850            4.3 %        376,563            4.4 %
Lease and rental expense                        88,848            0.9 %         84,967            1.0 %
Subtotal-operating expenses                  8,317,421           88.8 %      7,527,567           88.9 %
Income from operations                       1,049,445           11.2 %        944,395           11.1 %
Interest expense, net                           64,455            0.7 %         86,399            1.0 %
Other (income) expense, net                     (1,575 )         (0.0 )%         8,291            0.1 %
Income before income taxes                     986,565           10.5 %        849,705           10.0 %
Provision for income taxes                     232,844            2.5 %        204,649            2.4 %
Net income                                     753,721            8.0 %        645,056            7.6 %
Less: Income attributable to
noncontrolling interests                         1,255            0.0 %          9,811            0.1 %
Net income attributable to UHS             $   752,466            8.0 %    $   635,245            7.5 %




Net revenues increased 10.6%, or $895 million, to $9.367 billion during the
nine-month period ended September 30, 2021 as compared to $8.47 billion during
the first nine months of 2020. The net increase was primarily attributable to:
(i) a $857 million or 10.3% increase in net revenues generated from our acute
care hospital services and behavioral health services, on a same facility basis,
and; (ii) $38 million of other combined net increases which includes a $21
million increase in provider tax assessments which had no impact on net income
attributable to UHS as reflected above since the amounts offset between net
revenues and other operating expenses. Included in our net revenues during the
nine-month period ended September 30, 2020 was approximately $213 million of net
revenues recorded in connection with various governmental stimulus programs,
most notably the CARES, Act.

                                       34

--------------------------------------------------------------------------------

Income before income taxes (before deduction for income attributable to noncontrolling interests) increased $137 million to $987 million during the nine-month period ended September 30, 2021 as compared to $850 million during the comparable period of 2020. The $137 million net increase was due to:

• an increase of $136 million at our acute care facilities, as discussed below

in Acute Care Hospital Services;

• an increase of $7 million at our behavioral health care facilities, as


      discussed below in Behavioral Health Services, and;


  • $6 million of other combined net decreases.


Net income attributable to UHS increased $117 million to $752 million during the
nine-month period ended September 30, 2021 as compared to $635 million during
the comparable prior year period. This increase was attributable to:

• a $137 million increase in income before income taxes, as discussed above;

• an increase of $7 million due to a decrease in income attributable to

noncontrolling interests, and;

• a decrease of $28 million resulting from an increase in the provision for

income taxes due primarily to: (i) the income tax provision recorded in

connection with the $144 million increase in pre-tax income, partially

offset by; (ii) a $7 million decrease in the provision for income taxes

resulting from ASU 2016-09.

Increase to self-insured professional and general liability reserves:



Our estimated liability for self-insured professional and general liability
claims is based on a number of factors including, among other things, the number
of asserted claims and reported incidents, estimates of losses for these claims
based on recent and historical settlement amounts, estimates of incurred but not
reported claims based on historical experience, and estimates of amounts
recoverable under our commercial insurance policies.

As a result of unfavorable trends experienced during 2020 and 2021, included in our results of operations during the first nine months of 2021, was a $41 million increase to our reserves for self-insured professional and general liability claims ($36 million and $5 million recorded during the second and third quarter, respectively). During the first nine months of 2021, approximately $31 million of the reserves increase is included in our same facility basis acute care hospitals services' results and approximately $10 million is included in our behavioral health services' results.



Included in our results of operations during the first nine months of 2020, was
a $25 million increase to our reserves for self-insured professional and general
liability claims ($20 million and $5 million recorded during the first and third
quarters of 2020, respectively). Approximately $19 million of the increase to
our reserves was included in our same facility basis acute care hospitals
services' results during the first nine months of 2020 and approximately $6
million was included in our behavioral health services' results.

Acute Care Hospital Services

Same Facility Basis Acute Care Hospital Services



We believe that providing our results on a "Same Facility" basis (which is a
non-GAAP measure), which includes the operating results for facilities and
businesses operated in both the current year and prior year periods, is helpful
to our investors as a measure of our operating performance. Our Same Facility
results also neutralize (if applicable) the effect of items that are
non-operational in nature including items such as, but not limited to,
gains/losses on sales of assets and businesses, impacts of settlements, legal
judgments and lawsuits, impairments of long-lived and intangible assets and
other amounts that may be reflected in the current or prior year financial
statements that relate to prior periods.

Our Same Facility basis results reflected on the table below also exclude from
net revenues and other operating expenses, provider tax assessments incurred in
each period as discussed below Sources of Revenue-Various State Medicaid
Supplemental Payment Programs. However, these provider tax assessments are
included in net revenues and other operating expenses as reflected in the table
below under All Acute Care Hospital Services. The provider tax assessments had
no impact on the income before income taxes as reflected on the tables below
since the amounts offset between net revenues and other operating expenses. To
obtain a complete understanding of our financial performance, the Same Facility
results should be examined in connection with our net income as determined in
accordance with GAAP and as presented in the condensed consolidated financial
statements and notes thereto as contained in this Quarterly Report on Form
10-Q.

The following table summarizes the results of operations for our acute care
facilities on a same facility basis and is used in the discussion below for the
three and nine-month periods ended September 30, 2021 and 2020 (dollar amounts
in thousands):

                                       35

--------------------------------------------------------------------------------




                                          Three months ended             Three months ended             Nine months ended              Nine months ended
                                          September 30, 2021             September 30, 2020             September 30, 2021             September 30, 2020
                                                       % of Net                       % of Net                       % of Net                       % of Net
                                        Amount         Revenues        Amount         Revenues        Amount         Revenues        Amount         Revenues
Net revenues                          $ 1,792,862          100.0 %   $ 1,585,142          100.0 %   $ 5,178,594          100.0 %   $ 4,528,364          100.0 %
Operating charges:
Salaries, wages and benefits              755,216           42.1 %       660,610           41.7 %     2,153,046           41.6 %     1,909,216           42.2 %
Other operating expenses                  410,960           22.9 %       366,754           23.1 %     1,216,277           23.5 %     1,086,669           24.0 %
Supplies expense                          316,238           17.6 %       283,829           17.9 %       901,827           17.4 %       781,778           17.3 %
Depreciation and amortization              82,478            4.6 %        78,388            4.9 %       246,621            4.8 %       234,756            5.2 %
Lease and rental expense                   17,505            1.0 %        17,641            1.1 %        55,663            1.1 %        50,224            1.1 %
Subtotal-operating expenses             1,582,397           88.3 %     1,407,222           88.8 %     4,573,434           88.3 %     4,062,643           89.7 %
Income from operations                    210,465           11.7 %       177,920           11.2 %       605,160           11.7 %       465,721           10.3 %
Interest expense, net                         255            0.0 %           205            0.0 %           749            0.0 %         1,339            0.0 %
Other (income) expense, net                   436            0.0 %             -              -             436            0.0 %             0          

-


Income before income taxes            $   209,774           11.7 %   $   177,715           11.2 %   $   603,975           11.7 %   $   464,382

10.3 %

Three-month periods ended September 30, 2021 and 2020:



Included in our acute care hospital services' revenues during the third quarter
of 2020 was approximately $4 million of net revenues recorded in connection with
funds received from various governmental stimulus programs, most notably the
CARES Act. During the three-month period ended September 30, 2021, as compared
to the comparable prior year quarter, net revenues from our acute care hospital
services, on a same facility basis, increased $208 million, or 13.1% including
the governmental stimulus revenues recorded during the third quarter of 2020,
and increased $212 million, or 13.4% excluding the governmental stimulus
revenues recorded during the third quarter of 2020.

Income before income taxes (and before income attributable to noncontrolling
interests) increased $32 million, or 18%, amounting to $210 million, or 11.7% of
net revenues during the third quarter of 2021 as compared to $178 million, or
11.2% of net revenues during the third quarter of 2020.

During the three-month period ended September 30, 2021, excluding the impact of
the $4 million of governmental stimulus program revenues recorded during the
third quarter of 2020, net revenue per adjusted admission increased 1.3% while
net revenue per adjusted patient day increased 2.7%, as compared to the
comparable quarter of 2020. During the three-month period ended September 30,
2021, as compared to the comparable prior year quarter, inpatient admissions to
our acute care hospitals increased 9.9% and adjusted admissions (adjusted for
outpatient activity) increased 12.4%. Patient days at these facilities increased
8.4% and adjusted patient days increased 10.9% during the three-month period
ended September 30, 2021 as compared to the comparable prior year quarter. The
average length of inpatient stay at these facilities was 5.3 days and 5.4 days
during the three-month periods ended September 30, 2021 and 2020, respectively.
The occupancy rate, based on the average available beds at these facilities, was
71% and 67% during the three-month periods ended September 30, 2021 and 2020,
respectively.

Patient volumes at our acute care hospitals during the third quarter of 2021
included a continuation of relatively robust non-COVID patient volumes as well
as an increase in COVID-related patients as compared to volumes experienced
during the second quarter of 2021. The increased COVID-related patient volumes
resulted in increased revenues due to the higher acuity and incremental revenues
associated with COVID patients. However, unlike previous surges in COVID-related
patient volumes, non-COVID patient volumes experienced at our acute care
hospitals, including emergency department visits and elective procedures, were
generally consistent with pre-pandemic levels.

Nine-month periods ended September 30, 2021 and 2020:



During the nine-month period ended September 30, 2021, as compared to the
comparable prior year period, net revenues from our acute care hospital
services, on a same facility basis, increased $650 million, or 14.4%, including
the $161 million of governmental stimulus revenues recorded during the first
nine months of 2020, and increased $811 million, or 18.6%, excluding the
governmental stimulus revenues recorded during the first nine months of 2020.

Income before income taxes (and before income attributable to noncontrolling
interests) increased $140 million, or 30.1%, amounting to $604 million, or 11.7%
of net revenues during the first nine months of 2021 as compared to $464
million, or 10.3% of net revenues during the first nine months of 2020. As
mentioned above, included in our same facility basis acute care hospitals
services' results during the nine-month periods ended September 30, 2021 and
2020, was approximately $31 million and $20 million, respectively, related to
increases to our reserves for self-insured professional and general liability
claims. In addition, included in our same facility basis acute care hospitals
services' results during the first nine months of 2021 is approximately $25
million of income related to aggregate commercial insurance proceeds received
during the second and third quarters ($15 million and $10 million, respectively)
in

                                       36

--------------------------------------------------------------------------------

connection with the previously incurred, unfavorable economic impact resulting from the information technology incident that occurred during 2020, and the COVID-19 pandemic.



During the nine-month period ended September 30, 2021, excluding the impact of
the $161 million of governmental stimulus program revenues recorded during the
first nine months of 2020, net revenue per adjusted admission increased 10.4%
while net revenue per adjusted patient day increased 7.8%, as compared to the
comparable period of 2020. During the nine-month period ended September 30,
2021, as compared to the comparable prior year period, inpatient admissions to
our acute care hospitals increased 6.7% and adjusted admissions increased 7.3%.
Patient days at these facilities increased 9.2% and adjusted patient days
increased 9.9% during the nine-month period ended September 30, 2021 as compared
to the comparable prior year period. The average length of inpatient stay at
these facilities was 5.1 days and 5.0 days during the nine-month periods ended
September 30, 2021 and 2020, respectively. The occupancy rate, based on the
average available beds at these facilities, was 68% and 62% during the
nine-month periods ended September 30, 2021 and 2020, respectively.

All Acute Care Hospitals



The following table summarizes the results of operations for all our acute care
operations during the three and nine-month periods ended September 30, 2021 and
2020. These amounts include: (i) our acute care results on a same facility
basis, as indicated above; (ii) the impact of provider tax assessments which
increased net revenues and other operating expenses but had no impact on income
before income taxes, and; (iii) certain other amounts including, if applicable,
the results of recently acquired/opened ancillary facilities and businesses.
Dollar amounts below are reflected in thousands.





                                          Three months ended             Three months ended             Nine months ended              Nine months ended
                                          September 30, 2021             September 30, 2020             September 30, 2021             September 30, 2020
                                                       % of Net                       % of Net                       % of Net                       % of Net
                                        Amount         Revenues        Amount         Revenues        Amount         Revenues        Amount         Revenues
Net revenues                          $ 1,822,027          100.0 %   $ 1,610,003          100.0 %   $ 5,271,000          100.0 %   $ 4,598,558          100.0 %
Operating charges:
Salaries, wages and benefits              757,962           41.6 %       660,694           41.0 %     2,157,060           40.9 %     1,909,415           41.5 %
Other operating expenses                  436,475           24.0 %       391,642           24.3 %     1,305,544           24.8 %     1,156,909           25.2 %
Supplies expense                          316,950           17.4 %       283,827           17.6 %       902,654           17.1 %       781,776           17.0 %
Depreciation and amortization              83,794            4.6 %        78,388            4.9 %       248,462            4.7 %       234,756            5.1 %
Lease and rental expense                   17,518            1.0 %        17,641            1.1 %        55,676            1.1 %        50,224            1.1 %
Subtotal-operating expenses             1,612,699           88.5 %     1,432,192           89.0 %     4,669,396           88.6 %     4,133,080           89.9 %
Income from operations                    209,328           11.5 %       177,811           11.0 %       601,604           11.4 %       465,478           10.1 %
Interest expense, net                         255            0.0 %           205            0.0 %           749            0.0 %         1,339            0.0 %
Other (income) expense, net                   436            0.0 %             -              -             436            0.0 %             0          

-


Income before income taxes            $   208,637           11.5 %   $   177,606           11.0 %   $   600,419           11.4 %   $   464,139           10.1 %



Three-month periods ended September 30, 2021 and 2020:



During the three-month period ended September 30, 2021, as compared to the
comparable prior year quarter, net revenues from our acute care hospital
services increased $212 million, or 13.2% to $1.82 billion as compared to $1.61
billion due primarily to the $208 million, or 13.1% increase in same facility
revenues, as discussed above.

Income before income taxes increased $31 million, or 18%, to $209 million, or 11.5% of net revenues during the third quarter of 2021, as compared to $178 million, or 11.0% of net revenues during the third quarter of 2020. The $31 million increase in income before income taxes from our acute care hospital services resulted from the $32 million, or 18.0% increase in income before income taxes at our hospitals, on a same facility basis, as discussed above.

Nine-month periods ended September 30, 2021 and 2020:



During the nine-month period ended September 30, 2021, as compared to the
comparable prior year period, net revenues from our acute care hospital services
increased $672 million, or 14.6% to $5.27 billion as compared to $4.60 billion
due primarily to the $650 million, or 14.4% increase in same facility revenues,
as discussed above.

Income before income taxes increased $136 million, or 29% to $600 million, or
11.4% of net revenues during the first nine months of 2021, as compared to $464
million, or 10.1% of net revenues during the first nine months of 2020. The $136
million increase in income before income taxes from our acute care hospital
services resulted primarily from the $140 million, or 30.1% increase in income
before income taxes at our hospitals, on a same facility basis, as discussed
above.

Behavioral Health Services

Our Same Facility basis results (which is a non-GAAP measure), which include the
operating results for facilities and businesses operated in both the current
year and prior year period, neutralize (if applicable) the effect of items that
are non-operational in nature

                                       37

--------------------------------------------------------------------------------


including items such as, but not limited to, gains/losses on sales of assets and
businesses, impact of the reserve established in connection with the civil
aspects of the government's investigation of certain of our behavioral health
care facilities, impacts of settlements, legal judgments and lawsuits,
impairments of long-lived and intangible assets and other amounts that may be
reflected in the current or prior year financial statements that relate to prior
periods. Our Same Facility basis results reflected on the table below also
excludes from net revenues and other operating expenses, provider tax
assessments incurred in each period as discussed below Sources of
Revenue-Various State Medicaid Supplemental Payment Programs. However, these
provider tax assessments are included in net revenues and other operating
expenses as reflected in the table below under All Behavioral Health Care
Services. The provider tax assessments had no impact on the income before income
taxes as reflected on the tables below since the amounts offset between net
revenues and other operating expenses. To obtain a complete understanding of our
financial performance, the Same Facility results should be examined in
connection with our net income as determined in accordance with GAAP and as
presented in the condensed consolidated financial statements and notes thereto
as contained in this Quarterly Report on Form 10-Q.

The following table summarizes the results of operations for our behavioral
health care facilities, on a same facility basis, and is used in the discussions
below for the three and nine-month periods ended September 30, 2021 and 2020
(dollar amounts in thousands):

Same Facility-Behavioral Health



                                               Three months ended             Three months ended             Nine months ended              Nine months ended
                                               September 30, 2021             September 30, 2020             September 30, 2021             September 30, 2020
                                                            % of Net                       % of Net                       % of Net                        % of Net
                                             Amount         Revenues        Amount         Revenues        Amount         Revenues        Amount          Revenues
Net revenues                               $ 1,302,468          100.0 %   $ 1,276,568          100.0 %   $ 4,004,066          100.0 %   $ 3,797,579          100.0 %
Operating charges:
Salaries, wages and benefits                   721,949           55.4 %       683,567           53.5 %     2,133,755           53.3 %     2,022,066           53.2 %
Other operating expenses                       267,878           20.6 %       229,862           18.0 %       776,087           19.4 %       693,724           18.3 %
Supplies expense                                51,337            3.9 %        51,806            4.1 %       151,435            3.8 %       153,761            4.0 %
Depreciation and amortization                   45,798            3.5 %        43,919            3.4 %       136,926            3.4 %       129,877            3.4 %
Lease and rental expense                        10,311            0.8 %         9,928            0.8 %        31,339            0.8 %        31,384            0.8 %
Subtotal-operating expenses                  1,097,273           84.2 %     1,019,082           79.8 %     3,229,542           80.7 %     3,030,812           79.8 %
Income from operations                         205,195           15.8 %       257,486           20.2 %       774,524           19.3 %       766,767           20.2 %
Interest expense, net                              336            0.0 %           354            0.0 %         1,014            0.0 %         1,079            0.0 %
Other (income) expense, net                         27            0.0 %           526            0.0 %           435            0.0 %         2,337            0.1 %
Income before income taxes                 $   204,832           15.7 %   $   256,606           20.1 %   $   773,075           19.3 %   $   763,351           20.1 %

Three-month periods ended September 30, 2021 and 2020:



Included in our behavioral health services' revenues during the third quarter of
2020 was a $9 million reversal of revenues previously recorded in connection
with various governmental stimulus programs, most notably the CARES, Act. During
the three-month period ended September 30, 2021, as compared to the comparable
prior year quarter, net revenues from our behavioral health services, on a same
facility basis, increased $26 million or 2.0% including the governmental
stimulus revenue reversal recorded during the third quarter of 2020, and
increased $17 million or 1.3% excluding the governmental stimulus revenue
reversal recorded during the third quarter of 2020.

Income before income taxes (and before income attributable to noncontrolling
interests) decreased $52 million, or 20%, amounting to $205 million or 15.7% of
net revenues during the third quarter of 2021 as compared to $257 million or
20.1% of net revenues during the third quarter of 2020.

During the three-month period ended September 30, 2021, excluding the impact of
the $9 million of governmental stimulus program revenue reversal recorded during
the third quarter of 2020, net revenue per adjusted admission increased 4.2%
while net revenue per adjusted patient day increased 3.6%, as compared to the
comparable quarter of 2020. During the three-month period ended September 30,
2021, as compared to the comparable prior year quarter, inpatient admissions to
our behavioral health care hospitals decreased 2.8% and adjusted admissions
decreased 2.7%. Patient days at these facilities decreased 2.1% and adjusted
patient days decreased 2.1% during the three-month period ended September 30,
2021 as compared to the comparable prior year quarter. The average length of
inpatient stay at these facilities was 13.6 days and 13.5 days during the
three-month periods ended September 30, 2021 and 2020, respectively. The
occupancy rate, based on the average available beds at these facilities, was 70%
and 73% during the three-month periods ended September 30, 2021 and 2020,
respectively.

During the third quarter of 2021, patient volumes at our behavioral health care
hospitals were pressured by increased COVID-19 infections experienced in many of
our markets, as well as clinical staffing shortages caused by the general
unfavorable availability of workers in the U.S., as well as pandemic-related
staffing challenges experienced at many of our facilities. These staffing
pressures, together with COVID-related patient isolations, resulted in temporary
bed closures at certain facilities, as well as higher labor costs. The higher
labor costs are reflected in salaries, wages and benefits to the degree they
relate to our employees and are reflected in other operating expenses to the
degree they relate to contract payments to non-employees.

                                       38

--------------------------------------------------------------------------------


In addition, three of our behavioral health care facilities located in Louisiana
and Pennsylvania were damaged and temporarily closed (either entirely or
partially) as a result of Hurricane Ida in late August/early September of 2021.
Two of these facilities were fully re-opened by the end of September/October,
while the other facility is expected to be fully re-opened by mid-November. We
estimate that our pre-tax financial results during the third quarter of 2021
were unfavorably impacted by approximately $10 million as a result of the damage
sustained from Hurricane Ida.

Nine-month periods ended September 30, 2021 and 2020:



During the nine-month period ended September 30, 2021, as compared to the
comparable prior year quarter, net revenues from our behavioral health services,
on a same facility basis, increased $206 million or 5.4% including the $52
million of governmental stimulus revenues recorded during the third quarter of
2020, and increased $258 million or 6.9% excluding the governmental stimulus
revenues recorded during the third quarter of 2020.

Income before income taxes (and before income attributable to noncontrolling
interests) increased $10 million, or 1%, amounting to $773 million or 19.3% of
net revenues during the first nine months of 2021 as compared to $763 million or
20.1% of net revenues during the first nine months of 2020. As discussed below
in Sources of Revenue-Kentucky Hospital Rate Increase Program, included in our
same facility basis behavioral health services' results of operations during the
first nine months of 2021, is approximately $62 million of revenues recorded in
connection with the Kentucky Medicaid Managed Care Hospital Rate Increase
Program covering the period of July 1, 2020 to June 30, 2021. As also mentioned
above, included in our same facility basis behavioral health services' results
during the nine-month periods ended September 30, 2021 and 2020, was
approximately $10 million and $6 million, respectively, related to increases to
our reserves for self-insured professional and general liability claims.

During the nine-month period ended September 30, 2021, excluding the impact of
the $52 million of governmental stimulus program revenues recorded during the
first nine months of 2020, net revenue per adjusted admission increased 4.7%
while net revenue per adjusted patient day increased 6.0%, as compared to the
comparable period of 2020. During the nine-month period ended September 30,
2021, as compared to the comparable prior year period, inpatient admissions to
our behavioral health care hospitals increased 1.4% and adjusted admissions
increased 1.6%. Patient days at these facilities increased 0.1% and adjusted
patient days increased 0.3% during the nine-month period ended September 30,
2021 as compared to the comparable prior year period. The average length of
inpatient stay at these facilities was 13.5 days and 13.6 days during the
nine-month periods ended September 30, 2021 and 2020, respectively. The
occupancy rate, based on the average available beds at these facilities, was 71%
and 72% during the nine-month periods ended September 30, 2021 and 2020,
respectively.

All Behavioral Health Care Facilities



The following table summarizes the results of operations for all our behavioral
health care services during the three and nine-month periods ended September 30,
2021 and 2020. These amounts include: (i) our behavioral health care results on
a same facility basis, as indicated above; (ii) the impact of provider tax
assessments which increased net revenues and other operating expenses but had no
impact on income before income taxes, and; (iii) certain other amounts including
the results of facilities acquired or opened during the past year (if
applicable) as well as the results of certain facilities that were closed or
restructured during the past year. Dollar amounts below are reflected in
thousands.



                                               Three months ended             Three months ended             Nine months ended              Nine months ended
                                               September 30, 2021             September 30, 2020             September 30, 2021             September 30, 2020
                                                            % of Net                       % of Net                       % of Net                       % of Net
                                             Amount         Revenues        Amount         Revenues        Amount         Revenues        Amount         Revenues
Net revenues                               $ 1,328,293          100.0 %   $ 1,299,591          100.0 %   $ 4,075,127          100.0 %   $ 3,864,823          100.0 %
Operating charges:
Salaries, wages and benefits                   727,137           54.7 %       684,575           52.7 %     2,144,735           52.6 %     2,027,223           52.5 %
Other operating expenses                       292,794           22.0 %       253,779           19.5 %       847,780           20.8 %       765,006           19.8 %
Supplies expense                                51,712            3.9 %        51,858            4.0 %       152,273            3.7 %       153,861            4.0 %
Depreciation and amortization                   47,205            3.6 %        45,154            3.5 %       140,870            3.5 %       134,081            3.5 %
Lease and rental expense                        10,421            0.8 %        10,734            0.8 %        31,789            0.8 %        34,151            0.9 %
Subtotal-operating expenses                  1,129,269           85.0 %     1,046,100           80.5 %     3,317,447           81.4 %     3,114,322           80.6 %
Income from operations                         199,024           15.0 %       253,491           19.5 %       757,680           18.6 %       750,501           19.4 %
Interest expense, net                            1,218            0.1 %           433            0.0 %         3,564            0.1 %         1,184            0.0 %
Other (income) expense, net                         27            0.0 %           526            0.0 %           435            0.0 %         2,337            0.1 %
Income before income taxes                 $   197,779           14.9 %   $   252,532           19.4 %   $   753,681           18.5 %   $   746,980           19.3 %


                                       39

--------------------------------------------------------------------------------

Three-month periods ended September 30, 2021 and 2020:



During the three-month period ended September 30, 2021, as compared to the
comparable prior year quarter, net revenues generated from our behavioral health
services increased $29 million, or 2.2% due primarily to the above-mentioned $26
million, or 2.0% increase in net revenues on a same facility basis.

Income before income taxes decreased $55 million, or 21.7%, to $198 million or
14.9% of net revenues during the third quarter of 2021, as compared to $253
million or 19.4% of net revenues during the third quarter of 2020. The decrease
in income before income taxes at our behavioral health facilities during the
third quarter of 2021, as compared to the compared quarter of 2020, was
primarily attributable to the $52 million, or 20.2% decrease in income before
income taxes experienced at our behavioral health facilities on a same facility
basis, as discussed above.

Nine-month periods ended September 30, 2021 and 2020:



During the nine-month period ended September 30, 2021, as compared to the
comparable prior year period, net revenues generated from our behavioral health
services increased $210 million, or 5.4% due primarily to the above-mentioned
$206 million, or 5.4% increase in net revenues on a same facility basis.

Income before income taxes increased $7 million, or 0.9%, to $754 million or
18.5% of net revenues during the first nine months of 2021, as compared to $747
million or 19.3% of net revenues during the first nine months of 2020. The
increase in income before income taxes at our behavioral health facilities
during the first nine months of 2021, as compared to the compared period of
2020, was primarily attributable to the $10 million, or 1.3% increase in income
before income taxes experienced at our behavioral health facilities on a same
facility basis, as discussed above.

Sources of Revenue



Overview: We receive payments for services rendered from private insurers,
including managed care plans, the federal government under the Medicare program,
state governments under their respective Medicaid programs and directly from
patients.

Hospital revenues depend upon inpatient occupancy levels, the medical and
ancillary services and therapy programs ordered by physicians and provided to
patients, the volume of outpatient procedures and the charges or negotiated
payment rates for such services. Charges and reimbursement rates for inpatient
routine services vary depending on the type of services provided (e.g.,
medical/surgical, intensive care or behavioral health) and the geographic
location of the hospital. Inpatient occupancy levels fluctuate for various
reasons, many of which are beyond our control. The percentage of patient service
revenue attributable to outpatient services has generally increased in recent
years, primarily as a result of advances in medical technology that allow more
services to be provided on an outpatient basis, as well as increased pressure
from Medicare, Medicaid and private insurers to reduce hospital stays and
provide services, where possible, on a less expensive outpatient basis. We
believe that our experience with respect to our increased outpatient levels
mirrors the general trend occurring in the health care industry and we are
unable to predict the rate of growth and resulting impact on our future
revenues.

Patients are generally not responsible for any difference between customary
hospital charges and amounts reimbursed for such services under Medicare,
Medicaid, some private insurance plans, and managed care plans, but are
responsible for services not covered by such plans, exclusions, deductibles or
co-insurance features of their coverage. The amount of such exclusions,
deductibles and co-insurance has generally been increasing each year.
Indications from recent federal and state legislation are that this trend will
continue. Collection of amounts due from individuals is typically more difficult
than from governmental or business payers which unfavorably impacts the
collectability of our patient accounts.

As described below in the section titled 2019 Novel Coronavirus Disease Medicare
and Medicaid Payment Related Legislation, the federal government has enacted
multiple pieces of legislation to assist healthcare providers during the
COVID-19 world-wide pandemic and U.S. National Emergency declaration. We have
outlined those legislative changes related to Medicare and Medicaid payment and
their estimated impact on our financial results, where estimates are possible.

Sources of Revenues and Health Care Reform: Given increasing budget deficits,
the federal government and many states are currently considering additional ways
to limit increases in levels of Medicare and Medicaid funding, which could also
adversely affect future payments received by our hospitals. In addition, the
uncertainty and fiscal pressures placed upon the federal government as a result
of, among other things, impacts on state revenue and expenses resulting from the
COVID-19 pandemic, economic recovery stimulus packages, responses to natural
disasters, and the federal and state budget deficits in general may affect the
availability of government funds to provide additional relief in the future. We
are unable to predict the effect of future policy changes on our operations.

On March 23, 2010, President Obama signed into law the Legislation. Two primary
goals of the Legislation are to provide for increased access to coverage for
healthcare and to reduce healthcare-related expenses.

The Legislation revises reimbursement under the Medicare and Medicaid programs
to emphasize the efficient delivery of high quality care and contains a number
of incentives and penalties under these programs to achieve these goals. The
Legislation provides for decreases in the annual market basket update for
federal fiscal years 2010 through 2019, a productivity offset to the market
basket

                                       40

--------------------------------------------------------------------------------


update beginning October 1, 2011 for Medicare Part B reimbursable items and
services and beginning October 1, 2012 for Medicare inpatient hospital services.
The Legislation and subsequent revisions provide for reductions to both Medicare
DSH and Medicaid DSH payments. The Medicare DSH reductions began in October,
2013 while the Medicaid DSH reductions are scheduled to begin in 2024. The
Legislation implemented a value-based purchasing program, which will reward the
delivery of efficient care. Conversely, certain facilities will receive reduced
reimbursement for failing to meet quality parameters; such hospitals will
include those with excessive readmission or hospital-acquired condition rates.

A 2012 U.S. Supreme Court ruling limited the federal government's ability to
expand health insurance coverage by holding unconstitutional sections of the
Legislation that sought to withdraw federal funding for state noncompliance with
certain Medicaid coverage requirements. Pursuant to that decision, the federal
government may not penalize states that choose not to participate in the
Medicaid expansion by reducing their existing Medicaid funding. Therefore,
states can choose to expand or not to expand their Medicaid program without
risking the loss of federal Medicaid funding. As a result, many states,
including Texas, have not expanded their Medicaid programs without the threat of
loss of federal funding. CMS has previously granted section 1115 demonstration
waivers providing for work and community engagement requirements for certain
Medicaid eligible individuals. CMS has also released guidance to states
interested in receiving their Medicaid funding through a block grant mechanism.
The Biden administration has signaled its intent to withdraw previously issued
section 1115 demonstrations aligned with these policies. However, if
implemented, the previously issued section 1115 demonstrations are anticipated
to lead to reductions in coverage, and likely increases in uncompensated care,
in states where these demonstration waivers are granted.

On December 14, 2018, a Texas Federal District Court deemed the Legislation to
be unconstitutional in its entirety. The Court concluded that the Individual
Mandate is no longer permissible under Congress's taxing power as a result of
the Tax Cut and Jobs Act of 2017 ("TCJA") reducing the individual mandate's tax
to $0 (i.e., it no longer produces revenue, which is an essential feature of a
tax), rendering the Legislation unconstitutional. The court also held that
because the individual mandate is "essential" to the Legislation and is
inseverable from the rest of the law, the entire Legislation is
unconstitutional. Because the court issued a declaratory judgment and did not
enjoin the law, the Legislation remained in place pending its appeal. The
District Court for the Northern District of Texas ruling was appealed to the
U.S. Court of Appeals for the Fifth Circuit. On December 18, 2019, the Fifth
Circuit Court of Appeals' three-judge panel voted 2-1 to strike down the
Legislation individual mandate as unconstitutional. The Fifth Circuit Court also
sent the case back to the Texas district court to determine which Legislation
provisions should be stricken with the mandate or whether the entire Legislation
is unconstitutional. On March 2, 2020, the U.S. Supreme Court agreed to hear,
during the 2020-2021 term, two consolidated cases, filed by the State of
California and the United States House of Representatives, asking the U.S.
Supreme Court to review the ruling by the Fifth Circuit Court of Appeals. Oral
argument was heard on November 10, 2020, and on June 17, 2021, the U.S. Supreme
Court issued an opinion holding 7-2 that a group of states and individuals
lacked standing to challenge the constitutionality of the Affordable Care Act
("ACA"). The Court did not reach the plaintiffs' merits arguments, which
specifically challenged the constitutionality of the ACA's individual mandate
and the entirety of the ACA itself. As a result, the ACA will continue to be
law, and HHS and its respective agencies will continue to enforce regulations
implementing the law.

The various provisions in the Legislation that directly or indirectly affect
Medicare and Medicaid reimbursement are scheduled to take effect over a number
of years. The impact of the Legislation on healthcare providers will be subject
to implementing regulations, interpretive guidance and possible future
legislation or legal challenges. Certain Legislation provisions, such as that
creating the Medicare Shared Savings Program creates uncertainty in how
healthcare may be reimbursed by federal programs in the future. Thus, we cannot
predict the impact of the Legislation on our future reimbursement at this time
and we can provide no assurance that the Legislation will not have a material
adverse effect on our future results of operations.

The Legislation also contained provisions aimed at reducing fraud and abuse in
healthcare. The Legislation amends several existing laws, including the federal
Anti-Kickback Statute and the False Claims Act, making it easier for government
agencies and private plaintiffs to prevail in lawsuits brought against
healthcare providers. While Congress had previously revised the intent
requirement of the Anti-Kickback Statute to provide that a person is not
required to "have actual knowledge or specific intent to commit a violation of"
the Anti-Kickback Statute in order to be found in violation of such law, the
Legislation also provides that any claims for items or services that violate the
Anti-Kickback Statute are also considered false claims for purposes of the
federal civil False Claims Act. The Legislation provides that a healthcare
provider that retains an overpayment in excess of 60 days is subject to the
federal civil False Claims Act. The Legislation also expands the Recovery Audit
Contractor program to Medicaid. These amendments also make it easier for severe
fines and penalties to be imposed on healthcare providers that violate
applicable laws and regulations.

We have partnered with local physicians in the ownership of certain of our
facilities. These investments have been permitted under an exception to the
physician self-referral law. The Legislation permits existing physician
investments in a hospital to continue under a "grandfather" clause if the
arrangement satisfies certain requirements and restrictions, but physicians are
prohibited from increasing the aggregate percentage of their ownership in the
hospital. The Legislation also imposes certain compliance and disclosure
requirements upon existing physician-owned hospitals and restricts the ability
of physician-owned hospitals to expand the capacity of their facilities. As
discussed below, should the Legislation be repealed in its entirety, this aspect
of the Legislation would also be repealed restoring physician ownership of
hospitals and expansion right to its position and practice as it existed prior
to the Legislation.

                                       41

--------------------------------------------------------------------------------


The impact of the Legislation on each of our hospitals may vary. Because
Legislation provisions are effective at various times over the next several
years, we anticipate that many of the provisions in the Legislation may be
subject to further revision. Initiatives to repeal the Legislation, in whole or
in part, to delay elements of implementation or funding, and to offer amendments
or supplements to modify its provisions have been persistent. The ultimate
outcomes of legislative attempts to repeal or amend the Legislation and legal
challenges to the Legislation are unknown. Legislation has already been enacted
that eliminated the individual mandate penalty, effective January 1, 2019,
related to the obligation to obtain health insurance that was part of the
original Legislation. In addition, Congress previously considered legislation
that would, in material part: (i) eliminate the large employer mandate to offer
health insurance coverage to full-time employees; (ii) permit insurers to impose
a surcharge up to 30 percent on individuals who go uninsured for more than two
months and then purchase coverage; (iii) provide tax credits towards the
purchase of health insurance, with a phase-out of tax credits accordingly to
income level; (iv) expand health savings accounts; (v) impose a per capita cap
on federal funding of state Medicaid programs, or, if elected by a state,
transition federal funding to block grants, and; (vi) permit states to seek a
waiver of certain federal requirements that would allow such state to define
essential health benefits differently from federal standards and that would
allow certain commercial health plans to take health status, including
pre-existing conditions, into account in setting premiums.

In addition to legislative changes, the Legislation can be significantly
impacted by executive branch actions. President Biden is expected to undertake
executive actions that will strengthen the Legislation and may reverse the
policies of the prior administration. The Trump Administration had directed the
issuance of final rules (i) enabling the formation of health plans that would be
exempt from certain Legislation essential health benefits requirements; (ii)
expanding the availability of short-term, limited duration health insurance;
(iii) eliminating cost-sharing reduction payments to insurers that would
otherwise offset deductibles and other out-of-pocket expenses for health plan
enrollees at or below 250 percent of the federal poverty level; (iv) relaxing
requirements for state innovation waivers that could reduce enrollment in the
individual and small group markets and lead to additional enrollment in
short-term, limited duration insurance and association health plans; and (vi)
incentivizing the use of health reimbursement arrangements by employers to
permit employees to purchase health insurance in the individual market. The
uncertainty resulting from these Executive Branch policies led to reduced
Exchange enrollment in 2018, 2019 and 2020. To date, the Biden administration
has issued executive orders implementing a special enrollment period permitting
individuals to enroll in health plans outside of the annual open enrollment
period and reexamining policies that may undermine the ACA or the Medicaid
program. The ARPA's expansion of subsidies to purchase coverage through an
exchange is anticipated to increase exchange enrollment. The recent and on-going
COVID-19 pandemic and related U.S. National Emergency declaration may
significantly increase the number of uninsured patients treated at our
facilities extending beyond the most recent CBO published estimates due to
increased unemployment and loss of group health plan health insurance
coverage. It is also anticipated that these policies may create additional cost
and reimbursement pressures on hospitals.

It remains unclear what portions of the Legislation may remain, or whether any
replacement or alternative programs may be created by any future
legislation. Any such future repeal or replacement may have significant impact
on the reimbursement for healthcare services generally, and may create
reimbursement for services competing with the services offered by our
hospitals. Accordingly, there can be no assurance that the adoption of any
future federal or state healthcare reform legislation will not have a negative
financial impact on our hospitals, including their ability to compete with
alternative healthcare services funded by such potential legislation, or for our
hospitals to receive payment for services.

For additional disclosure related to our revenues including a disaggregation of
our consolidated net revenues by major source for each of the periods presented
herein, please see Note 12 to the Consolidated Financial Statements-Revenue.

Medicare: Medicare is a federal program that provides certain hospital and
medical insurance benefits to persons aged 65 and over, some disabled persons
and persons with end-stage renal disease. All of our acute care hospitals and
many of our behavioral health centers are certified as providers of Medicare
services by the appropriate governmental authorities. Amounts received under the
Medicare program are generally significantly less than a hospital's customary
charges for services provided. Since a substantial portion of our revenues will
come from patients under the Medicare program, our ability to operate our
business successfully in the future will depend in large measure on our ability
to adapt to changes in this program.

Under the Medicare program, for inpatient services, our general acute care
hospitals receive reimbursement under the inpatient prospective payment system
("IPPS"). Under the IPPS, hospitals are paid a predetermined fixed payment
amount for each hospital discharge. The fixed payment amount is based upon each
patient's Medicare severity diagnosis related group ("MS-DRG"). Every MS-DRG is
assigned a payment rate based upon the estimated intensity of hospital resources
necessary to treat the average patient with that particular diagnosis. The
MS-DRG payment rates are based upon historical national average costs and do not
consider the actual costs incurred by a hospital in providing care. This MS-DRG
assignment also affects the predetermined capital rate paid with each MS-DRG.
The MS-DRG and capital payment rates are adjusted annually by the predetermined
geographic adjustment factor for the geographic region in which a particular
hospital is located and are weighted based upon a statistically normal
distribution of severity. While we generally will not receive payment from
Medicare for inpatient services, other than the MS-DRG payment, a hospital may
qualify for an "outlier" payment if a particular patient's treatment costs are
extraordinarily high and exceed a specified threshold. MS-DRG rates are adjusted
by an update factor each federal fiscal year, which begins on October 1. The
index used to adjust the MS-DRG rates, known as the "hospital market basket
index," gives consideration to the inflation experienced by hospitals

                                       42

--------------------------------------------------------------------------------


in purchasing goods and services. Generally, however, the percentage increases
in the MS-DRG payments have been lower than the projected increase in the cost
of goods and services purchased by hospitals.

In August, 2021, CMS published its IPPS 2022 final payment rule which provides
for a 2.7% market basket increase to the base Medicare MS-DRG blended rate. When
statutorily mandated budget neutrality factors, annual geographic wage index
updates, documenting and coding adjustments, and adjustments mandated by the
Legislation are considered, without consideration for the required Medicare DSH
payments changes and increase to the Medicare Outlier threshold, the overall
final increase in IPPS payments is approximately 2.5%. Including DSH payments
and certain other adjustments, we estimate our overall increase from the final
IPPS 2022 rule (covering the period of October 1, 2021 through September 30,
2022) will approximate 1.5%. This projected impact from the IPPS 2022 final rule
includes an increase of approximately 0.5% to partially restore cuts made as a
result of the American Taxpayer Relief Act of 2012 ("ATRA"), as required by the
21st Century Cures Act but excludes the impact of the sequestration reductions
related to the 2011 Act, Bipartisan Budget Act of 2015, and Bipartisan Budget
Act of 2018, as discussed below.

In September, 2020, CMS published its IPPS 2021 final payment rule which
provides for a 2.4% market basket increase to the base Medicare MS-DRG blended
rate. When statutorily mandated budget neutrality factors, annual geographic
wage index updates, documenting and coding adjustments, and adjustments mandated
by the Legislation are considered, without consideration for the required
Medicare DSH payments changes and increase to the Medicare Outlier threshold,
the overall increase in IPPS payments is approximately 1.8%. Including DSH
payments and certain other adjustments, we estimate our overall increase from
the final IPPS 2021 rule (covering the period of October 1, 2020 through
September 30, 2021) will approximate 2.3%. This projected impact from the IPPS
2021 final rule includes an increase of approximately 0.5% to partially restore
cuts made as a result of ATRA, as required by the 21st Century Cures Act but
excludes the impact of the sequestration reductions related to the 2011 Act,
Bipartisan Budget Act of 2015, and Bipartisan Budget Act of 2018.



In the final rule, CMS will require hospitals to report certain market-based
payment rate information for Medicare Advantage organizations on their Medicare
cost report for cost reporting periods ending on or after January 1, 2021, to be
used in a potential change to the methodology for calculating the IPPS MS-DRG
relative weights to reflect relative market-based pricing, beginning in FY 2024.

In August, 2019, CMS published its IPPS 2020 final payment rule which provides
for a 3.0% market basket increase to the base Medicare MS-DRG blended rate. When
statutorily mandated budget neutrality factors, annual geographic wage index
updates, documenting and coding adjustments, and adjustments mandated by the
Legislation are considered, without consideration for the required Medicare DSH
payments changes and increase to the Medicare Outlier threshold, the overall
increase in IPPS payments is approximately 2.8%. Including DSH payments and
certain other adjustments, we estimate our overall increase from the final IPPS
2020 rule (covering the period of October 1, 2019 through September 30, 2020)
will approximate 2.1%. This projected impact from the IPPS 2020 final rule
includes an increase of approximately 0.5% to partially restore cuts made as a
result ATRA, as required by the 21st Century Cures Act but excludes the impact
of the sequestration reductions related to the 2011 Act, Bipartisan Budget Act
of 2015, and Bipartisan Budget Act of 2018, as discussed below. CMS completed
its full phase-in to use uncompensated care data from the 2015 Worksheet S-10
hospital cost reports to allocate approximately $8.5 billion in the DSH
Uncompensated Care Pool.

In June, 2019, the Supreme Court of the United States issued a decision
favorable to hospitals impacting prior year Medicare DSH payments (Azar v.
Allina Health Services, No. 17-1484 (U.S. Jun. 3, 2019)). In Allina, the
hospitals challenged the Medicare DSH adjustments for federal fiscal year 2012,
specifically challenging CMS's decision to include inpatient hospital days
attributable to Medicare Part C enrollee patients in the numerator and
denominator of the Medicare/SSI fraction used to calculate a hospital's DSH
payments. This ruling addresses CMS's attempts to impose the policy espoused in
its vacated 2004 rulemaking to a fiscal year in the 2004-2013 time period
without using notice-and-comment rulemaking. This decision should require CMS to
recalculate hospitals' DSH Medicare/SSI fractions, with Medicare Part C days
excluded, for at least federal fiscal year 2012, but likely federal fiscal years
2005 through 2013. In August, 2020, CMS issued a rule that proposed to
retroactively negate the effects of the aforementioned Supreme Court decision,
which rule has yet to be finalized. Although we can provide no assurance that we
will ultimately receive additional funds, we estimate that the favorable impact
of this court ruling on certain prior year hospital Medicare DSH payments could
range between $18 million to $28 million in the aggregate.

The 2011 Act included the imposition of annual spending limits for most federal
agencies and programs aimed at reducing budget deficits by $917 billion between
2012 and 2021, according to a report released by the Congressional Budget
Office. Among its other provisions, the law established a bipartisan
Congressional committee, known as the Joint Committee, which was responsible for
developing recommendations aimed at reducing future federal budget deficits by
an additional $1.5 trillion over 10 years. The Joint Committee was unable to
reach an agreement by the November 23, 2011 deadline and, as a result,
across-the-board cuts to discretionary, national defense and Medicare spending
were implemented on March 1, 2013 resulting in Medicare payment reductions of up
to 2% per fiscal year. Recent legislation suspended payment reductions through
December 31, 2021, in exchange for extended cuts through 2030.

Inpatient services furnished by psychiatric hospitals under the Medicare program
are paid under a Psychiatric Prospective Payment System ("Psych PPS"). Medicare
payments to psychiatric hospitals are based on a prospective per diem rate with
adjustments to

                                       43

--------------------------------------------------------------------------------

account for certain facility and patient characteristics. The Psych PPS also contains provisions for outlier payments and an adjustment to a psychiatric hospital's base payment if it maintains a full-service emergency department.



In July, 2021, CMS published its Psych PPS final rule for the federal fiscal
year 2022. Under this final rule, payments to our psychiatric hospitals and
units are estimated to increase by 2.2% compared to federal fiscal year 2021.
This amount includes the effect of the 2.0% net market basket update which
reflects the offset of a 0.7% productivity adjustment.

In July, 2020, CMS published its Psych PPS final rule for the federal fiscal
year 2021. Under this final rule, payments to our psychiatric hospitals and
units are estimated to increase by 2.2% compared to federal fiscal year 2020.
This amount includes the effect of the 2.2% market basket update.

In July, 2019, CMS published its Psych PPS final rule for the federal fiscal
year 2020. Under this final rule, payments to our psychiatric hospitals and
units are estimated to increase by 1.7% compared to federal fiscal year 2019.
This amount includes the effect of the 2.9% market basket update less a 0.75%
adjustment as required by the ACA and a 0.4% productivity adjustment.

CMS's calendar year 2018 final OPPS rule, issued on November 13, 2017,
substantially reduced Medicare Part B reimbursement for 340B Program drugs paid
to hospitals. Beginning January 1, 2018, CMS reimbursement for certain
separately payable drugs or biologicals that are acquired through the 340B
Program by a hospital paid under the OPPS (and not excepted from the payment
adjustment policy) is the average sales price of the drug or biological minus
22.5 percent, an effective reduction of 26.89% in payments for 340B program
drugs. In December, 2018, the U.S. District Court for the District of Columbia
ruled that HHS did not have statutory authority to implement the 2018 Medicare
OPPS rate reduction related to hospitals that qualify for drug discounts under
the federal 340B Program and granted a permanent injunction against the payment
reduction. On July 31, 2020, the U.S. Court of Appeals for the D.C. Circuit
reversed the District Court and held that HHS's decision to lower drug
reimbursement rates for 340B hospitals rests on a reasonable interpretation of
the Medicare statute. No further legal challenges are available to the
plaintiffs and, as a result, we recognized $8 million of revenues during 2020
that were previously reserved in a prior year.

On November 2, 2021, CMS issued its OPPS final rule for 2022. The hospital
market basket increase is 2.7% and the productivity adjustment reduction is
-0.7% for a net market basket increase of 2.0%. When other statutorily required
adjustments and hospital patient service mix are considered, we estimate that
our overall Medicare OPPS update for 2022 will aggregate to a net increase of
2.4% which includes a 3.0% increase to behavioral health division partial
hospitalization rates.

In December, 2020, CMS published its OPPS final rule for 2021. The hospital
market basket increase is 2.4% and there is no productivity adjustment reduction
to the 2021 OPPS market basket. When other statutorily required adjustments and
hospital patient service mix are considered, we estimate that our overall
Medicare OPPS update for 2021 will aggregate to a net increase of 3.3% which
includes a 9.2% increase to behavioral health division partial hospitalization
rates.

In November, 2019, CMS published its OPPS final rule for 2020. The hospital
market basket increase is 3.0%. The Medicare statute requires a productivity
adjustment reduction of 0.4% to the 2020 OPPS market basket resulting in a 2020
update to OPPS payment rates by 2.6%. When other statutorily required
adjustments and hospital patient service mix are considered, we estimate that
our overall Medicare OPPS update for 2020 will aggregate to a net increase of
2.7% which includes a 7.7% increase to behavioral health division partial
hospitalization rates. When the behavioral health division's partial
hospitalization rate impact is excluded, we estimate that our Medicare 2020 OPPS
payments will result in a 1.9% increase in payment levels for our acute care
division, as compared to 2019. For CY 2020, CMS will use the FY 2020 hospital
IPPS post-reclassified wage index for urban and rural areas as the wage index
for the OPPS to determine the wage adjustments for both the OPPS payment rate
and the copayment standardized amount.

In November, 2019, CMS finalized its Hospital Price Transparency rule that
implements certain requirements under the June 24, 2019 Presidential Executive
Order related to Improving Price and Quality Transparency in American Healthcare
to Put Patients First. Under this final rule, effective January 1, 2021, CMS
will require: (1) hospitals make public their standard changes (both gross
charges and payer-specific negotiated charges) for all items and services online
in a machine-readable format, and; (2) hospitals to make public standard charge
data for a limited set of "shoppable services" the hospital provides in a form
and manner that is more consumer friendly. On November 2, 2021, CMS released a
final rule increasing the monetary penalty that CMS can impose on hospitals that
fail to comply with the price transparency requirements. We believe that our
hospitals are in full compliance with the applicable federal regulations.

Medicaid: Medicaid is a joint federal-state funded health care benefit program
that is administered by the states to provide benefits to qualifying
individuals. Most state Medicaid payments are made under a PPS-like system, or
under programs that negotiate payment levels with individual hospitals. Amounts
received under the Medicaid program are generally significantly less than a
hospital's customary charges for services provided. In addition to revenues
received pursuant to the Medicare program, we receive a large portion of our
revenues either directly from Medicaid programs or from managed care companies
managing Medicaid. All of our acute care hospitals and most of our behavioral
health centers are certified as providers of Medicaid services by the
appropriate governmental authorities.

                                       44

--------------------------------------------------------------------------------


We receive revenues from various state and county based programs, including
Medicaid in all the states in which we operate (we receive Medicaid revenues in
excess of $100 million annually from each of California, Texas, Nevada,
Washington, D.C., Pennsylvania, Illinois, Florida and Massachusetts);
CMS-approved Medicaid supplemental programs in certain states including Texas,
Mississippi, Illinois, Oklahoma, Nevada, Arkansas, California, Kentucky and
Indiana, and; state Medicaid disproportionate share hospital payments in certain
states including Texas and South Carolina. We are therefore particularly
sensitive to potential reductions in Medicaid and other state based revenue
programs as well as regulatory, economic, environmental and competitive changes
in those states. We can provide no assurance that reductions to revenues earned
pursuant to these programs, particularly in the above-mentioned states, will not
have a material adverse effect on our future results of operations.

The Legislation substantially increases the federally and state-funded Medicaid
insurance program, and authorizes states to establish federally subsidized
non-Medicaid health plans for low-income residents not eligible for Medicaid
starting in 2014. However, the Supreme Court has struck down portions of the
Legislation requiring states to expand their Medicaid programs in exchange for
increased federal funding. Accordingly, many states in which we operate have not
expanded Medicaid coverage to individuals at 133% of the federal poverty level.
Facilities in states not opting to expand Medicaid coverage under the
Legislation may be additionally penalized by corresponding reductions to
Medicaid disproportionate share hospital payments beginning in 2020, as
discussed below. We can provide no assurance that further reductions to Medicaid
revenues, particularly in the above-mentioned states, will not have a material
adverse effect on our future results of operations.

On November 12, 2019, CMS issued the proposed Medicaid Fiscal Accountability
Rule ("MFAR") which CMS believed would strengthen the fiscal integrity of the
Medicaid program and help ensure that state supplemental payments and financing
arrangements are transparent and value-driven. In January, 2021, CMS issued a
formal notice of withdrawal of this proposed rule.

In January, 2020, CMS announced a new opportunity to support states with greater
flexibility to improve the health of their Medicaid populations. The new 1115
Waiver Block Grant Type Demonstration program, titled Healthy Adult Opportunity
("HAO"), emphasizes the concept of value-based care while granting states
extensive flexibility to administer and design their programs within a defined
budget. CMS believes this state opportunity will enhance the Medicaid program's
integrity through its focus on accountability for results and quality
improvement, making the Medicaid program stronger for states and beneficiaries.
The Biden administration has signaled its intent to withdraw the HAO
demonstration. Accordingly, we are unable to predict whether the HAO
demonstration will impact our future results of operations.



Various State Medicaid Supplemental Payment Programs:



We incur health-care related taxes ("Provider Taxes") imposed by states in the
form of a licensing fee, assessment or other mandatory payment which are related
to: (i) healthcare items or services; (ii) the provision of, or the authority to
provide, the health care items or services, or; (iii) the payment for the health
care items or services. Such Provider Taxes are subject to various federal
regulations that limit the scope and amount of the taxes that can be levied by
states in order to secure federal matching funds as part of their respective
state Medicaid programs. As outlined below, we derive a related Medicaid
reimbursement benefit from assessed Provider Taxes in the form of Medicaid
claims based payment increases and/or lump sum Medicaid supplemental payments.

Included in these Provider Tax programs are reimbursements received in connection with the Texas Uncompensated Care/Upper Payment Limit program ("UC/UPL") and Texas Delivery System Reform Incentive Payments program ("DSRIP"). Additional disclosure related to the Texas UC/UPL and DSRIP programs is provided below.

Texas Uncompensated Care/Upper Payment Limit Payments:



Certain of our acute care hospitals located in various counties of Texas
(Grayson, Hidalgo, Maverick, Potter and Webb) participate in Medicaid
supplemental payment Section 1115 Waiver indigent care programs. Section 1115
Waiver Uncompensated Care ("UC") payments replace the former Upper Payment Limit
("UPL") payments. These hospitals also have affiliation agreements with
third-party hospitals to provide free hospital and physician care to qualifying
indigent residents of these counties. Our hospitals receive both supplemental
payments from the Medicaid program and indigent care payments from third-party,
affiliated hospitals. The supplemental payments are contingent on the county or
hospital district making an Inter-Governmental Transfer ("IGT") to the state
Medicaid program while the indigent care payment is contingent on a transfer of
funds from the applicable affiliated hospitals. However, the county or hospital
district is prohibited from entering into an agreement to condition any IGT on
the amount of any private hospital's indigent care obligation.

On December 21, 2017, CMS approved the 1115 Waiver for the period January 1,
2018 to September 30, 2022. The Waiver continued to include UC and DSRIP payment
pools with modifications and new state specific reporting deadlines that if not
met by THHSC will result in material decreases in the size of the UC and DSRIP
pools. For UC during the initial two years of this renewal, the UC program will
remain relatively the same in size and allocation methodology. For year three of
this waiver renewal, FFY 2020, and through FFY 2022, the size and distribution
of the UC pool will be determined based on charity care costs reported to HHSC
in accordance with Medicare cost report Worksheet S-10 principles. In September
2019, CMS approved the annual UC pool size in the amount of $3.9 billion for
demonstration years ("DYs") 9, 10 and 11 (October 1, 2019 to September 30,
2022).

                                       45

--------------------------------------------------------------------------------


On April 16, 2021, CMS rescinded its January 15, 2021, 1115 Waiver ten year
expedited renewal approval that was effective through September 30, 2030. In
July, 2021, HHSC submitted another 1115 Waiver renewal application to CMS which
reflects the same terms and conditions agreed to by CMS on January 15, 2021, in
order to receive an extension beyond September 30, 2022.

Effective April 1, 2018, certain of our acute care hospitals located in Texas
began to receive Medicaid managed care rate enhancements under the Uniform
Hospital Rate Increase Program ("UHRIP"). The non-federal share component of
these UHRIP rate enhancements are financed by Provider Taxes. The Texas 1115
Waiver rules require UHRIP rate enhancements be considered in the Texas UC
payment methodology which results in a reduction to our UC payments. The UC
amounts reported in the State Medicaid Supplemental Payment Program Table below
reflect the impact of this new UHRIP program. In July 2020, THHSC announced CMS
approval of an increase to UHRIP pool for the state's 2021 fiscal year to $2.7
billion from its current funding level of $1.6 billion. We estimate that this
UHRIP pool increase will not have a material impact on the Company financial
results due to CMS approved pool allocation methodology for the SFY 2021
program.

On March 26, 2021, HHSC published a final rule that will apply to program
periods on or after September 1, 2021, and UHRIP will be re-named the
Comprehensive Hospital Increase Reimbursement Program ("CHIRP"). CHIRP will be
comprised of a UHRIP component and an Average Commercial Incentive Award
("ACIA") component. HHSC has proposed a pool size of $5.0 billion subject to CMS
approval. The Company is not able to estimate the financial impact of the
program change.

On January 11, 2021, HHSC announced that CMS approved the pre-print modification
that HHSC submitted for UHRIP period March 1, 2021 through August 31, 2021. CMS
approved rate changes that will now increase rates for private Institutions of
Mental Disease ("IMD") for services provided to patients under age 21 or
patients 65 years of age or older. The impact of this program is included in the
Medicaid Supplemental Payment Programs table below.

On September 24, 2021, HHSC finalized New Fee-for-Service Supplemental Payment
Program: Hospital Augmented Reimbursement Program ("HARP") to be effective
October 1, 2021. The HARP program continues the financial transition for
providers who have historically participated in the Delivery System Reform
Incentive Payment program described below. The program will provide additional
funding to hospitals to help offset the cost hospitals incur while providing
Medicaid services. HHSC financial model released concurrent with the publication
of the final rule indicates net potential incremental Medicaid reimbursements to
us of approximately $15 million annually, without consideration of any potential
adverse impact on future Medicaid DSH or Medicaid UC payments. This program is
subject to CMS approval.

Texas Delivery System Reform Incentive Payments:



In addition, the Texas Medicaid Section 1115 Waiver includes a DSRIP pool to
incentivize hospitals and other providers to transform their service delivery
practices to improve quality, health status, patient experience, coordination,
and cost-effectiveness. DSRIP pool payments are incentive payments to hospitals
and other providers that develop programs or strategies to enhance access to
health care, increase the quality of care, the cost-effectiveness of care
provided and the health of the patients and families served. In May, 2014, CMS
formally approved specific DSRIP projects for certain of our hospitals for
demonstration years 3 to 5 (our facilities did not materially participate in the
DSRIP pool during demonstration years 1 or 2). DSRIP payments are contingent on
the hospital meeting certain pre-determined milestones, metrics and clinical
outcomes. Additionally, DSRIP payments are contingent on a governmental entity
providing an IGT for the non-federal share component of the DSRIP payment. THHSC
generally approves DSRIP reported metrics, milestones and clinical outcomes on a
semi-annual basis in June and December. Under the CMS approval noted above, the
Waiver renewal requires the transition of the DSRIP program to one focused on
"health system performance measurement and improvement." THHSC must submit a
transition plan describing "how it will further develop its delivery system
reforms without DSRIP funding and/or phase out DSRIP funded activities and meet
mutually agreeable milestones to demonstrate its ongoing progress." The size of
the DSRIP pool will remain unchanged for the initial two years of the waiver
renewal with unspecified decreases in years three and four of the renewal, FFY
2020 and 2021, respectively. In FFY 2022, DSRIP funding under the waiver is
eliminated. During the second quarter of 2021, we recorded $13 million in
incremental DSRIP revenues in connection with notification that we received from
the THHSC that our DSRIP participant hospitals had met additional DSRIP project
metrics. For FFY 2022, we will no longer receive DSRIP funds due to the
elimination of this funding source by CMS in the Waiver renewals except for
certain carryover DSRIP projects for which achievement of the required metrics
will not be known until state fiscal year 2022. In March, 2020, HHSC submitted a
DSRIP Transition Plan to CMS as required by the 1115 Waiver Special Terms and
Conditions #37 that outlines a transition from the current DSRIP program to a
Value-Based Purchasing ("VBP") type payment model. As noted above, HHSC
finalized a rule to make changes to existing UHRIP program. This rule change
reflects HHSC's effort to comply with federal regulations that require
directed-payment programs to advance goals included in the state's Medicaid
managed care quality strategy and to align with the ongoing efforts to
transition from the Delivery System Reform Incentive Payment program. We are
unable to estimate the financial impact of this payment change.



Summary of Amounts Related To The Above-Mentioned Various State Medicaid Supplemental Payment Programs:



The following table summarizes the revenues, Provider Taxes and net benefit
related to each of the above-mentioned Medicaid supplemental programs for the
three and nine-month periods ended September 30, 2021 and 2020. The Provider
Taxes are recorded in other operating expenses on the Condensed Consolidated
Statements of Income as included herein.

                                       46

--------------------------------------------------------------------------------


                                                            (amounts in millions)
                                          Three Months Ended                      Nine Months Ended
                                   September 30,      September 30,        September 30,      September 30,
                                       2021               2020                 2021               2020
Texas UC/UPL:
Revenues                          $            40    $            29      $           107    $            85
Provider Taxes                                (12 )               (9 )                (31 )              (25 )
Net benefit                       $            28    $            20      $            76    $            60

Texas DSRIP:
Revenues                          $             0    $             0      $            44    $            29
Provider Taxes                                  0                  0                  (14 )               (9 )
Net benefit                       $             0    $             0      $            30    $            20

Various other state programs:
Revenues                          $            83    $           107      $           317    $           249
Provider Taxes                                (36 )              (39 )               (111 )             (101 )
Net benefit                       $            47    $            68      $           206    $           148

Total all Provider Tax programs:
Revenues                          $           123    $           136      $           468    $           363
Provider Taxes                                (48 )              (48 )               (156 )             (135 )
Net benefit                       $            75    $            88      $           312    $           228




We estimate that our aggregate net benefit from the Texas and various other
state Medicaid supplemental payment programs will approximate $389 million (net
of Provider Taxes of $207 million) during the year ending December 31, 2021.
This amount includes approximately $62 million related to the Kentucky Hospital
Rate Increase Program, as described below. These amounts are based upon various
terms and conditions that are out of our control including, but not limited to,
the states'/CMS's continued approval of the programs and the applicable hospital
district or county making IGTs consistent with 2020 levels. Future changes to
these terms and conditions could materially reduce our net benefit derived from
the programs which could have a material adverse impact on our future
consolidated results of operations. In addition, Provider Taxes are governed by
both federal and state laws and are subject to future legislative changes that,
if reduced from current rates in several states, could have a material adverse
impact on our future consolidated results of operations. As described below in
2019 Novel Coronavirus Disease Medicare and Medicaid Payment Related
Legislation, a 6.2% increase to the Medicaid Federal Matching Assistance
Percentage ("FMAP") is included in the Families First Coronavirus Response Act.
The impact of the enhanced FMAP Medicaid supplemental and DSH payments are
reflected in our results for year ended December 31, 2020 and for the three and
nine-month periods ended September 30, 2021. We are unable to estimate the
prospective financial impact of this provision at this time as our financial
impact is contingent on unknown state action during future eligible federal
fiscal quarters.

Texas and South Carolina Medicaid Disproportionate Share Hospital Payments:



Hospitals that have an unusually large number of low-income patients (i.e.,
those with a Medicaid utilization rate of at least one standard deviation above
the mean Medicaid utilization, or having a low income patient utilization rate
exceeding 25%) are eligible to receive a DSH adjustment. Congress established a
national limit on DSH adjustments. Although this legislation and the resulting
state broad-based provider taxes have affected the payments we receive under the
Medicaid program, to date the net impact has not been materially adverse.

Upon meeting certain conditions and serving a disproportionately high share of
Texas' and South Carolina's low income patients, five of our facilities located
in Texas and one facility located in South Carolina received additional
reimbursement from each state's DSH fund. The South Carolina and Texas DSH
programs were renewed for each state's 2022 DSH fiscal year (covering the period
of October 1, 2021 through September 30, 2022).

In connection with these DSH programs, included in our financial results was an
aggregate of approximately $12 million and $10 million during the three-month
periods ended September 30, 2021 and 2020, respectively, and $35 million during
each of the nine-month periods ended September 30, 2021 and 2020. We expect the
aggregate reimbursements to our hospitals pursuant to the Texas and South
Carolina 2021 fiscal year programs to be approximately $48 million.

                                       47

--------------------------------------------------------------------------------


The Legislation and subsequent federal legislation provides for a significant
reduction in Medicaid disproportionate share payments beginning in federal
fiscal year 2024 (see above in Sources of Revenues and Health Care
Reform-Medicaid Revisions for additional disclosure related to the delay of
these DSH reductions). HHS is to determine the amount of Medicaid DSH payment
cuts imposed on each state based on a defined methodology. As Medicaid DSH
payments to states will be cut, consequently, payments to Medicaid-participating
providers, including our hospitals in Texas and South Carolina, will be reduced
in the coming years. Based on the CMS final rule published in September, 2019,
beginning in fiscal year 2024 (as amended by the CARES Act and the CAA), annual
Medicaid DSH payments in South Carolina and Texas could be reduced by
approximately 74% and 44%, respectively, from 2020 DSH payment levels.



Our behavioral health care facilities in Texas have been receiving Medicaid DSH
payments since FFY 2016. As with all Medicaid DSH payments, hospitals are
subject to state audits that typically occur up to three years after their
receipt. DSH payments are subject to a federal Hospital Specific Limit ("HSL")
and are not fully known until the DSH audit results are concluded. In general,
freestanding psychiatric hospitals tend to provide significantly less charity
care than acute care hospitals and therefore are at more risk for retroactive
recoupment of prior year DSH payments in excess of their respective HSL. In
light of the retroactive HSL audit risk for freestanding psychiatric hospitals,
we have established DSH reserves for our facilities that have been receiving
funds since FFY 2016. These DSH reserves are also impacted by the resolution of
federal DSH litigation related to Children's Hospital Association of Texas v.
Azar ("CHAT"), No. 17-cv-844 (D.D.C. March 2, 2018), appeal docketed, No.
18-5135 (D.C. Cir. May 9, 2018) where the calculation of HSL was being
challenged. In August, 2019, DC Circuit Court of Appeals issued a unanimous
decision in CHAT and reversed the judgment of the district court in favor of CMS
and ordered that CMS's "2017 Rule" (regarding Medicaid DSH Payments-Treatment of
Third Party Payers in Calculating Uncompensated Care Costs) be reinstated. CMS
has not issued any additional guidance post the ruling. In April 2020, the
plaintiffs in the case have petitioned the Supreme Court of the United States to
hear their case. Additionally, there have been separate legal challenges on this
same issue in the Fifth and Eight Circuits. On November 4, 2019, the United
States Court of Appeals for the Eighth Circuit issued an opinion upholding the
2017 Rule. Missouri Hosp. Ass'n v. Azar, No. 18-1778 (8th Cir. Nov. 4, 2019)
(i.e. reversing a district court order enjoining the 2017 rule). On April 20,
2020, the United States Court of Appeals of the Fifth Circuit issued a decision
also upholding the 2017 Rule. Baptist Memorial Hospital v. Azar, No. 18-60592
(5th Cir. April 20, 2020). In light of these court decisions, we continue to
maintain reserves in the financial statements for cumulative Medicaid DSH and UC
reimbursements related to our behavioral health hospitals located in Texas that
amounted to $41 million and $37 million as of September 30, 2021 and 2020,
respectively.

Nevada SPA:



In Nevada, CMS approved a state plan amendment ("SPA") in August, 2014 that
implemented a hospital supplemental payment program retroactive to January 1,
2014. This SPA has been approved for additional state fiscal years including the
2021 fiscal year covering the period of July 1, 2020 through June 30, 2021. CMS
approval for the 2022 fiscal year, which is still pending, is expected to occur.

In connection with this program, included in our financial results was
approximately $5 million and $6 million during the three-month periods ended
September 30, 2021 and 2020, respectively, and $16 million and $20 million
during the nine-month periods ended September 30, 2021 and 2020, respectively.
We estimate that our reimbursements pursuant to this program will approximate
$20 million during the year ended December 31, 2021.

California SPA:



In California, CMS issued formal approval of the 2017-19 Hospital Fee Program in
December, 2017 retroactive to January 1, 2017 through September 30, 2019. In
September, 2019, the state submitted a request to renew the Hospital Fee Program
for the period July 1, 2019 to December 31, 2021. On February 25, 2020, CMS
approved this renewed program. These approvals include the Medicaid inpatient
and outpatient fee-for-service supplemental payments and the overall provider
tax structure but did not yet include the approval of the managed care rate
setting payment component for certain rate periods (see table below). The
managed care payment component consists of two categories of payments,
"pass-through" payments and "directed" payments. The pass-through payments are
similar in nature to the prior Hospital Fee Program payment method whereas the
directed payment method will be based on actual concurrent hospital Medicaid
managed care in-network patient volume.

                                       48

--------------------------------------------------------------------------------

California Hospital Fee Program CMS Approval Status:

Hospital Fee Program CMS Methodology CMS Rate Setting Approval


      Component          Approval Status              Status
Fee For Service        Approved through     Approved through December
Payment                December 31, 2021    31, 2021; Paid through
                                            March 31, 2021
Managed                Approved through     Approved through June 30,
Care-Pass-Through      December 31, 2021    2017; Paid in advance of
Payment                                     approval through December
                                            31, 2020
Managed Care-Directed  Approved through     Approved through June 30,
Payment                December 31, 2020    2017; Paid in advance of
                                            approval through December
                                            31, 2019




In connection with the existing program, included in our financial results was
approximately $11 million and $35 million for the three-month periods ending
September 30, 2021 and 2020, respectively, and $35 million and $49 million
during the nine-month periods ended September 30, 2021 and 2020, respectively.
We estimate that our reimbursements pursuant to this program will approximate
$46 million during the year ended December 31, 2021. The aggregate impact of the
California supplemental payment program, as outlined above, is included in the
above State Medicaid Supplemental Payment Program table.

In April, 2020, the California Department of Health Care Services ("DHCS")
notified hospital providers that participate in the Medicaid managed care
directed payment program that DHCS would recalculate directed payments for the
period of July 1, 2017 through September 30, 2018 ("SFY 2018") to remedy an
identified data error. In August, 2020, as a follow-up to that notification,
DHCS issued its corrected directed payment calculations. The updated calculation
resulted in a favorable adjustment to the above program year and also resulted
in increased expected supplemental payment amount for program years subsequent
to the recalculated SFY 2018 rate period. The California Hospital Fee amounts
noted above include our portion of the state corrected data.

Kentucky Hospital Rate Increase Program ("HRIP"):



As previously disclosed in early 2021, CMS approved the Kentucky Medicaid
Managed Care Hospital Rate Increase Program ("HRIP") for SFY 2021, which covered
the period of July 1, 2020 through June 30, 2021. This program change increased
our reimbursement for SFY 2021 by an aggregate of approximately $62 million, of
which $55 million and $7 million were recorded by us during the second and third
quarter of 2021, respectively.

Programs such as HRIP require an annual state submission and approval by CMS. In
May, 2021, Kentucky submitted a request to CMS in order to continue the HRIP
program for SFY 2022 with a similar payment methodology and payment level as the
SFY 2021 program. Although we believe the CMS approval process is in progress,
we are unable to predict if CMS will ultimately approve the HRIP for SFY 2022,
and if approved, if the rates will be generally comparable to the SFY 2021 HRIP
rates.

Florida Medicaid Managed Care Directed Payment Program ("DPP"):



During the fourth quarter of 2021, we expect to record approximately $25 million
of increased reimbursement as a result of recent CMS approval of the Medicaid
managed care directed payment program for the 2021 rate period (October 1, 2020
to September 30, 2021). Various DPP related legislative and regulatory approvals
result in the retroactive payment of the increased reimbursement after the
applicable rate year has ended. The payment methodology and amount of the 2022
DPP (covering the period of October 1, 2021 to September 30, 2022) is expected
to be comparable to the 2021 DPP. As a result, if CMS and other legislative and
regulatory approvals occur in connection with the 2022 program, we may be
entitled to increased reimbursement during 2022 in an amount comparable to the
$25 million expected for the 2021 DPP.

Risk Factors Related To State Supplemental Medicaid Payments:



As outlined above, we receive substantial reimbursement from multiple states in
connection with various supplemental Medicaid payment programs. The states
include, but are not limited to, Texas, Mississippi, Illinois, Nevada, Arkansas,
California and Indiana. Failure to renew these programs beyond their scheduled
termination dates, failure of the public hospitals to provide the necessary IGTs
for the states' share of the DSH programs, failure of our hospitals that
currently receive supplemental Medicaid revenues to qualify for future funds
under these programs, or reductions in reimbursements, could have a material
adverse effect on our future results of operations.

In April, 2016, CMS published its final Medicaid Managed Care Rule which
explicitly permits but phases out the use of pass-through payments (including
supplemental payments) by Medicaid Managed Care Organizations ("MCO") to
hospitals over ten years but allows for a transition of the pass-through
payments into value-based payment structures, delivery system reform initiatives
or payments tied to services under a MCO contract. Since we are unable to
determine the financial impact of this aspect of the final rule, we can provide
no assurance that the final rule will not have a material adverse effect on our
future results of operations. In

                                       49

--------------------------------------------------------------------------------

November, 2020, CMS issued a final rule permitting pass-through supplemental provider payments during a time-limited period when states transition populations or services from fee-for-service Medicaid to managed care.



HITECH Act: In July 2010, the Department of Health and Human Services ("HHS")
published final regulations implementing the health information technology
("HIT") provisions of the American Recovery and Reinvestment Act (referred to as
the "HITECH Act"). The final regulation defines the "meaningful use" of
Electronic Health Records ("EHR") and establishes the requirements for the
Medicare and Medicaid EHR payment incentive programs. The final rule established
an initial set of standards and certification criteria. The implementation
period for these Medicare and Medicaid incentive payments started in federal
fiscal year 2011 and can end as late as 2016 for Medicare and 2021 for the state
Medicaid programs. State Medicaid program participation in this federally funded
incentive program is voluntary but all of the states in which our eligible
hospitals operate have chosen to participate. Our acute care hospitals qualified
for these EHR incentive payments upon implementation of the EHR application
assuming they meet the "meaningful use" criteria. The government's ultimate goal
is to promote more effective (quality) and efficient healthcare delivery through
the use of technology to reduce the total cost of healthcare for all Americans
and utilizing the cost savings to expand access to the healthcare system.

All of our acute care hospitals have met the applicable meaningful use
criteria.  However, under the HITECH Act, hospitals must continue to meet the
applicable meaningful use criteria in each fiscal year or they will be subject
to a market basket update reduction in a subsequent fiscal year. Failure of our
acute care hospitals to continue to meet the applicable meaningful use criteria
would have an adverse effect on our future net revenues and results of
operations.

In the 2019 IPPS final rule, CMS overhauled the Medicare and Medicaid EHR
Incentive Program to focus on interoperability, improve flexibility, relieve
burden and place emphasis on measures that require the electronic exchange of
health information between providers and patients. We can provide no assurance
that the changes will not have a material adverse effect on our future results
of operations.

Managed Care: A significant portion of our net patient revenues are generated
from managed care companies, which include health maintenance organizations,
preferred provider organizations and managed Medicare (referred to as Medicare
Part C or Medicare Advantage) and Medicaid programs. In general, we expect the
percentage of our business from managed care programs to continue to grow. The
consequent growth in managed care networks and the resulting impact of these
networks on the operating results of our facilities vary among the markets in
which we operate. Typically, we receive lower payments per patient from managed
care payers than we do from traditional indemnity insurers, however, during the
past few years we have secured price increases from many of our commercial
payers including managed care companies.

Commercial Insurance: Our hospitals also provide services to individuals covered
by private health care insurance. Private insurance carriers typically make
direct payments to hospitals or, in some cases, reimburse their policy holders,
based upon the particular hospital's established charges and the particular
coverage provided in the insurance policy. Private insurance reimbursement
varies among payers and states and is generally based on contracts negotiated
between the hospital and the payer.

Commercial insurers are continuing efforts to limit the payments for hospital
services by adopting discounted payment mechanisms, including predetermined
payment or DRG-based payment systems, for more inpatient and outpatient
services. To the extent that such efforts are successful and reduce the
insurers' reimbursement to hospitals and the costs of providing services to
their beneficiaries, such reduced levels of reimbursement may have a negative
impact on the operating results of our hospitals.

Surprise Billing Interim Final Rule: On September 30, 2021, the Department of
Health and Human Services ("HHS"), the Department of Labor, and the Department
of the Treasury (collectively, the Departments), along with the Office of
Personnel Management ("OPM"), released an interim final rule with comment
period, entitled "Requirements Related to Surprise Billing; Part II." This rule
is related to Title I (the No Surprises Act) of Division BB of the Consolidated
Appropriations Act, 2021, and establishes new protections from surprise billing
and excessive cost sharing for consumers receiving health care items/services.
It implements additional protections against surprise medical bills under the No
Surprises Act, including provisions related to the independent dispute
resolution process, good faith estimates for uninsured (or self-pay)
individuals, the patient-provider dispute resolution process, and expanded
rights to external review. We do not expect this interim final rule to have a
material impact on our results of operations.

Other Sources: Our hospitals provide services to individuals that do not have
any form of health care coverage. Such patients are evaluated, at the time of
service or shortly thereafter, for their ability to pay based upon federal and
state poverty guidelines, qualifications for Medicaid or other state assistance
programs, as well as our local hospitals' indigent and charity care policy.
Patients without health care coverage who do not qualify for Medicaid or
indigent care write-offs are offered substantial discounts in an effort to
settle their outstanding account balances.

Health Care Reform: Listed below are the Medicare, Medicaid and other health
care industry changes which have been, or are scheduled to be, implemented as a
result of the Legislation.


Implemented Medicare Reductions and Reforms:






                                       50

--------------------------------------------------------------------------------

• The Legislation reduced the market basket update for inpatient and outpatient

hospitals and inpatient behavioral health facilities by 0.25% in each of 2010 and

2011, by 0.10% in each of 2012 and 2013, 0.30% in 2014, 0.20% in each of 2015 and

2016 and 0.75% in each of 2017, 2018 and 2019.

• The Legislation implemented certain reforms to Medicare Advantage payments,


    effective in 2011.
  • A Medicare shared savings program, effective in 2012.
  • A hospital readmissions reduction program, effective in 2012.
  • A value-based purchasing program for hospitals, effective in 2012.
  • A national pilot program on payment bundling, effective in 2013.

• Reduction to Medicare DSH payments, effective in 2014, as discussed above.





Medicaid Revisions:


• Expanded Medicaid eligibility and related special federal payments,

effective in 2014.

• The Legislation (as amended by subsequent federal legislation) requires annual

aggregate reductions in federal DSH funding from federal fiscal year ("FFY")

2024 through FFY 2027. Medicaid DSH reductions have been delayed several times.

Commencing in federal fiscal year 2024, and continuing through 2027, DSH

payments will be reduced by $8 billion annually.

Health Insurance Revisions:

• Large employer insurance reforms, effective in 2015.

• Individual insurance mandate and related federal subsidies, effective in 2014.

As noted above in Health Care Reform, the Tax Cuts and Jobs Act enacted into

law in December, 2017 eliminated the individual insurance federal mandate

penalty beginning January 1, 2019.

• Federally mandated insurance coverage reforms, effective in 2010 and forward.




The Legislation seeks to increase competition among private health insurers by
providing for transparent federal and state insurance exchanges. The Legislation
also prohibits private insurers from adjusting insurance premiums based on
health status, gender, or other specified factors. We cannot provide assurance
that these provisions will not adversely affect the ability of private insurers
to pay for services provided to insured patients, or that these changes will not
have a negative material impact on our results of operations going forward.

Value-Based Purchasing:



There is a trend in the healthcare industry toward value-based purchasing of
healthcare services. These value-based purchasing programs include both public
reporting of quality data and preventable adverse events tied to the quality and
efficiency of care provided by facilities. Governmental programs including
Medicare and Medicaid currently require hospitals to report certain quality data
to receive full reimbursement updates. In addition, Medicare does not reimburse
for care related to certain preventable adverse events. Many large commercial
payers currently require hospitals to report quality data, and several
commercial payers do not reimburse hospitals for certain preventable adverse
events.

The Legislation required HHS to implement a value-based purchasing program for
inpatient hospital services which became effective on October 1, 2012. The
Legislation requires HHS to reduce inpatient hospital payments for all
discharges by 2% in FFY 2017 and subsequent years. HHS will pool the amount
collected from these reductions to fund payments to reward hospitals that meet
or exceed certain quality performance standards established by HHS. HHS will
determine the amount each hospital that meets or exceeds the quality performance
standards will receive from the pool of dollars created by these payment
reductions. As part of the FFY 2022 IPPS final rule described above, and as a
result of the on-going COVID-19 pandemic, CMS has implemented a budget neutral
payment policy to fully offset the 2% VBP withhold during FFY 2022.



Hospital Acquired Conditions:



The Legislation prohibits the use of federal funds under the Medicaid program to
reimburse providers for medical assistance provided to treat hospital acquired
conditions ("HAC"). Beginning in FFY 2015, hospitals that fall into the top 25%
of national risk-adjusted HAC rates for all hospitals in the previous year will
receive a 1% reduction in their total Medicare payments.

Readmission Reduction Program:



                                       51

--------------------------------------------------------------------------------


In the Legislation, Congress also mandated implementation of the hospital
readmission reduction program ("HRRP"). Hospitals with excessive readmissions
for conditions designated by HHS will receive reduced payments for all inpatient
discharges, not just discharges relating to the conditions subject to the
excessive readmission standard. The HRRP currently assesses penalties on
hospitals having excess readmission rates for heart failure, myocardial
infarction, pneumonia, acute exacerbation of chronic obstructive pulmonary
disease (COPD) and elective total hip arthroplasty (THA) and/or total knee
arthroplasty (TKA), excluding planned readmissions, when compared to expected
rates. In the fiscal year 2015 IPPS final rule, CMS added readmissions for
coronary artery bypass graft (CABG) surgical procedures beginning in fiscal year
2017. To account for excess readmissions, an applicable hospital's base
operating DRG payment amount is adjusted for each discharge occurring during the
fiscal year. Readmissions payment adjustment factors can be no more than a 3
percent reduction.

Accountable Care Organizations:



The Legislation requires HHS to establish a Medicare Shared Savings Program that
promotes accountability and coordination of care through the creation of
accountable care organizations ("ACOs"). The ACO program allows providers
(including hospitals), physicians and other designated professionals and
suppliers to voluntarily work together to invest in infrastructure and redesign
delivery processes to achieve high quality and efficient delivery of services.
The program is intended to produce savings as a result of improved quality and
operational efficiency. ACOs that achieve quality performance standards
established by HHS will be eligible to share in a portion of the amounts saved
by the Medicare program. CMS is also developing and implementing more advanced
ACO payment models, such as the Next Generation ACO Model, which require ACOs to
assume greater risk for attributed beneficiaries. On December 21, 2018, CMS
published a final rule that, in general, requires ACO participants to take on
additional risk associated with participation in the program. On April 30, 2020,
CMS issued an interim final rule with comment in response to the COVID-19
national emergency permitting ACOs with current agreement periods expiring on
December 31, 2020 the option to extend their existing agreement period by one
year, and permitting certain ACOs to retain their participation level through
2021. It remains unclear to what extent providers will pursue federal ACO status
or whether the required investment would be warranted by increased payment.

Bundled Payments for Care Improvement Advanced:

The Center for Medicare & Medicaid Innovation ("CMMI") implemented a new, second
generation voluntary episode payment model, Bundled Payments for Care
Improvement Advanced ("BPCI-Advanced" or the "Program"), with the first
performance period beginning October 1, 2018. BPCI-Advanced is designed to test
a new iteration of bundled payments with an aim to align incentives among
participating health care providers to reduce expenditures and improve quality
of care for traditional Medicare beneficiaries.

During the fourth quarter of 2020, CMS restructured the FY2021 to FY2023 program
and required participants to select from eight Clinical Episode Service Line
Groups instead of individual clinical episodes. CMS also announced that the now
voluntary program would become mandatory in 2024.

For our hospitals that participated in the program, the CMS BPCI-A reconciliation for the period October 1, 2018 through December 31, 2020 did not have a material impact on our financial results.



The ultimate success and financial impact of the BPCI-Advanced program is
contingent on multiple variables so we are unable to estimate the future impact.
However, given the breadth and scope of participation of our acute care
hospitals in BPCI-Advanced, the impact could be significant (either favorably or
unfavorably) depending on actual program results.



2019 Novel Coronavirus Disease Medicare and Medicaid Payment Related Legislation



In response to the growing threat of COVID-19, on March 13, 2020 a national
emergency was declared. The declaration empowered the HHS Secretary to waive
certain Medicare, Medicaid and Children's Health Insurance Program ("CHIP")
program requirements and Medicare conditions of participation under Section 1135
of the Social Security Act. Having been granted this authority by HHS, CMS
issued a broad range of blanket waivers, which eased certain requirements for
impacted providers, including:



• Waivers and Flexibilities for Hospitals and other Healthcare Facilities

including those for physical environment requirements and certain Emergency


      Medical Treatment & Labor Act provisions


  • Provider Enrollment Flexibilities

• Flexibility and Relief for State Medicaid Programs including those under


      section 1135 Waivers


  • Suspension of Certain Enforcement Activities



In addition to the national emergency declaration, Congress passed and Presidents Trump and Biden have signed various forms of legislation intended to support state and local authority responses to COVID-19 as well as provide fiscal support to businesses, individuals, financial markets, hospitals and other healthcare providers.

Some of the financial support included in the various legislative actions include:





  • Medicaid FMAP Enhancement


                                       52

--------------------------------------------------------------------------------




     •            The FMAP was increased by 6.2% retroactive to the 

federal fiscal


           quarter beginning January 1, 2020 and each   subsequent federal fiscal
           quarter for all states and U.S. territories during the declared public
           health emergency, in accordance with specified conditions.


  • Public Health Emergency Declaration


     •     The HHS Secretary renewed the public health emergency ("PHE") effective
           October 18, 2021 for ninety (90) days. As a result, states would be
           eligible for the enhanced FMAP through the end of federal fiscal
           quarter ending March 31, 2022 should the PHE not be rescinded by the
           Secretary before the end of the ninety day period.



• Creation of a $250 billion Public Health and Social Services Emergency Fund

("PHSSEF")

• Makes grants available to hospitals and other healthcare providers to


           cover unreimbursed healthcare related expenses or lost revenues
           attributable to the public health emergency resulting from the
           coronavirus.

• During 2021, we received approximately $189 million in PHSSEF grants


           from the federal government as provided for by the CARES Act. As
           previously disclosed, we returned these funds to HHS during the 

second


           quarter of 2021. Since our intent was to return these funds, our
           results of operations for during the three and nine-month 

periods ended

September 30, 2021 include no impact from the receipt of the 

funds.


           Included in our results of operations for the three and 

nine-month


           periods ended September 30, 2021 was approximately $3 million and $16
           million, respectively, of revenues recognized in connection with funds
           received from various state and local governmental stimulus grant
           programs.

• During the year ended December 31, 2020, we received approximately $417


           million of funds from various governmental stimulus programs, most
           notably the PHSSEF as provided for by the CARES Act. Included in our
           results of operations for the year ended December 31, 2020 was
           approximately $413 million of revenues recognized in connection with
           funds received from these federal, state and local governmental
           stimulus programs. Our results of operations for the three-month period
           ended September 30, 2020 included a reversal of approximately $5
           million of previously recognized revenues in connection with these
           governmental stimulus programs; and our results of operations for the
           nine-month period ended September 30, 2020 included

approximately $213


           million of revenues recorded in connection with these 

governmental


           stimulus programs.


• All PHSSEF receipts are pursuant to meeting the applicable the terms and conditions of


            the various distribution programs as of September 30, 2021. The 

Consolidated


            Appropriations Act, 2021 (H.R. 133) enacted on December 27, 

2020 includes language that


            provides specific instructions on: (1) the redistribution of 

PHSSEF grant payments by a


            parent company among its subsidiaries, and; (2) the calculation 

of lost revenue in a


            PHSSEF grant entitlement determination. The HHS terms and 

conditions for all grant


            recipients and specific fund distributions are located at
            

https://www.hhs.gov/coronavirus/cares-act-provider-relief-fund/for-providers/index.html

• Reimburse hospitals at Medicare rates for uncompensated COVID-19 care for

the uninsured

• Our operating results for the three and nine-month periods ended

September 30, 2021 included $11 million and $42 million, 

respectively,


           of revenues in connection with this program. During the year ended
           December 31, 2020, we recorded $29 million in connection with this
           program, approximately $9 million and $11 million of which were
           included in our operating results for the three and nine-month periods
           ended September 30, 2020, respectively. Revenue for the eligible
           patient encounters is recorded in the period in which the

encounter is


           deemed eligible for this program net of any normal accounting reserves.




  • Medicare Sequestration Relief


     •     Suspension of the 2% Medicare sequestration offset for Medicare
           services provided from May 1, 2020 through December 31, 2021 by various
           legislative extensions.

• We estimate that this provision had a favorable impact of approximately

$11 million and $34 million during the three and nine-month 

periods


           ended September 30, 2021, respectively, and will have a 

favorable


           impact of approximately $11 million over the remaining three 

months of


           2021. We estimate that this provision had a favorable impact of $30
           million during the year ended December 31, 2020, approximately $11
           million and $19 million of which was included in our results of
           operations during the three and nine-month periods ended

September 30,


           2020, respectively.




  • Medicare add-on for inpatient hospital COVID-19 patients

• Increases the payment that would otherwise be made to a hospital for


           treating a Medicare patient admitted with COVID-19 by twenty percent
           (20%) for the duration of the COVID-19 public health emergency.


                                       53

--------------------------------------------------------------------------------


     •     For the three and nine-month periods ended September 30, 2021, we
           estimate that additional payments under this provision were
           approximately $8 million and $27 million, respectively. For the year
           ended December 31, 2020, we estimate that additional payments under
           this provision were approximately $32 million, approximately $13
           million and $18 million of which were included in our results of
           operations during the three and nine-month periods ended

September 30,


           2020, respectively. These payments offset the increased expenses
           associated with the treatment of Medicare COVID-19 patients.




  • Expansion of the Medicare Accelerated and Advance Payment Program ("MAAPP")


     •     In March, 2021, we fully repaid the $695 million of Medicare
           Accelerated payments received during 2020.




In addition to statutory and regulatory changes to the Medicare program and each
of the state Medicaid programs, our operations and reimbursement may be affected
by administrative rulings, new or novel interpretations and determinations of
existing laws and regulations, post-payment audits, requirements for utilization
review and new governmental funding restrictions, all of which may materially
increase or decrease program payments as well as affect the cost of providing
services and the timing of payments to our facilities. The final determination
of amounts we receive under the Medicare and Medicaid programs often takes many
years, because of audits by the program representatives, providers' rights of
appeal and the application of numerous technical reimbursement provisions. We
believe that we have made adequate provisions for such potential adjustments.
Nevertheless, until final adjustments are made, certain issues remain unresolved
and previously determined allowances could become either inadequate or more than
ultimately required.

Finally, we expect continued third-party efforts to aggressively manage reimbursement levels and cost controls. Reductions in reimbursement amounts received from third-party payers could have a material adverse effect on our financial position and our results.

Other Operating Results

Interest Expense:

As reflected on the schedule below, interest expense was $21 million and $25 million during the three-month periods ended September 30, 2021 and 2020, respectively, and $64 million and $86 million during the nine-month periods ended September 30, 2021 and 2020, respectively (amounts in thousands):



                                             Three Months        Three Months         Nine Months         Nine Months
                                                 Ended               Ended               Ended               Ended
                                             September 30,       September 30,       September 30,       September 30,
                                                 2021                2020                2021                2020
Revolving credit & demand notes (a.)        $           502     $           510     $         1,502     $         1,737
$700 million, 4.75% Senior Notes due
2022, net (b.)                                            -               7,792                   -              23,932
$400 million, 5.00% Senior Notes due 2026
(c.)                                                  4,000               5,000              14,000              15,000
$800 million, 2.65% Senior Notes due 2030
(d.)                                                  5,356                 532              16,113                 532
$700 million, 1.65% Senior Notes due 2026
(e.)                                                  1,205                   -               1,205                   -
$500 million, 2.65% Senior Notes due 2032
(f.)                                                  1,376                   -               1,376                   -
Tranche A term loan facility (a.)                     6,460               7,584              20,576              31,023
Tranche B term loan facility (a.)                     1,352               2,410               5,941               9,511
Accounts receivable securitization
program (g.)                                             10                 406                 777               3,032
Subtotal-revolving credit, demand notes,
Senior Notes,
  term loan facilities and accounts
receivable
  securitization program                             20,261              24,234              61,490              84,767
Amortization of financing fees                        1,087               1,305               3,205               3,865
Other combined interest expense                       1,322                 580               4,197               1,685
Capitalized interest on major projects               (1,305 )            (1,024 )            (2,957 )            (3,051 )
Interest income                                        (166 )              (520 )            (1,480 )              (867 )
Interest expense, net                       $        21,199     $        24,575     $        64,455     $        86,399




    (a.) In August, 2021, we entered into a seventh amendment to our credit

agreement dated November 15, 2010, as amended, which provided for the

amendment and restatement of the previously existing credit facility. In

September, 2021, we entered into an eight amendment to our credit

agreement which modified the definition of "Adjusted LIBO Rate". The

seventh amendment, provided for, among other things, the following: (i) a

$1.2 billion aggregate amount revolving credit facility that is scheduled

to mature in August, 2026, representing an increase of $200 million over

the $1.0 billion previous commitment (no borrowings outstanding as of

September 30, 2021); (ii) a $1.7 billion tranche A term loan facility

that is scheduled to mature in August, 2026, resulting in a reduction of

$150 million from the $1.85 billion of borrowings outstanding under the


         previous tranche A term loan facility, and; (iii) repayment of
         approximately $488 million of


                                       54

--------------------------------------------------------------------------------

borrowings outstanding under the previous tranche B term loan facility. The

$638 million net repayment of borrowings under the tranche A and tranche B

term loan facilities in connection with the seventh amendment ($150 million

and $488 million, respectively), were funded utilizing a portion of the

proceeds generated from the August, 2021 issuance of the $700 million,


       1.65% Senior Notes due in 2026, and the $500 million, 2.65%, Senior Notes
       due in 2032.




    (b.) In September, 2020, we redeemed the entire $700 million aggregate

principal amount of our previously outstanding 4.75% Senior Secured Notes


         that were scheduled to mature in 2022.




    (c.) In September, 2021, we redeemed the entire $400 million aggregate

principal amount of our previously outstanding 5.00% Senior Secured Notes

that were scheduled to mature in 2026 ("2026 Notes") at a cash redemption


         price equal to the sum of: (i) 102.50% of the aggregate principal amount
         of the 2026 Notes redeemed, and; (ii) accrued and unpaid interest on the

2026 Notes to the redemption date. This redemption was funded utilizing a

portion of the proceeds generated from the August, 2021 issuance of the

$700 million, 1.65% Senior Notes due in 2026, and the $500 million, 2.65%


         Senior Notes due in 2032, as discussed in (e.) and (f.) below.



(d.) In September, 2020, we completed the offering of $800 million aggregate


         principal amount of 2.65% Senior Notes due in 2030.



(e.) In August, 2021, we completed the offering of $700 million aggregate


         principal amount of 1.65% Senior Notes due in 2026.



(f.) In August, 2021, we completed the offering of $500 million aggregate


         principal amount of 2.65% Senior Notes due in 2032.



(g.) Our accounts receivable securitization program was amended in April, 2021

to reduce the borrowing commitment to $20 million (from $450 million

previously) and to extend the maturity date to April 25, 2022. There are


         no outstanding borrowings as of September 30, 2021.




Interest expense decreased approximately $3 million during the three-month
period ended September 30, 2021, as compared to the comparable quarter of 2020,
due primarily to: (i) a net $4 million decrease in aggregate interest expense on
our revolving credit, demand notes, senior notes, term loan facilities and
accounts receivable securitization program resulting from a decrease in our
aggregate average cost of borrowings pursuant to these facilities (2.13% during
the third quarter of 2021 as compared to 2.67% in the comparable quarter of
2020), offset by an increase in the aggregate average outstanding borrowings
($3.70 billion during the third quarter of 2021 as compared to $3.59 billion
during the comparable quarter of 2020), and; (ii) $1 million of other combined
net increases in interest expense.



Interest expense decreased $22 million during the nine-month period ended
September 30, 2021 as compared to the comparable prior year period of 2020,
primarily due to: (i) a net $23 million decrease in aggregate interest expense
on our revolving credit, demand notes, senior notes, term loan facilities and
accounts receivable securitization program resulting from a decrease in our
aggregate average cost of borrowings pursuant to these facilities (2.19% during
the first nine months of 2021 as compared to 3.06% during the comparable period
of 2020), as well as a slight increase in the aggregate average outstanding
borrowings ($3.69 billion during the nine months ended September 30, 2021 as
compared to $3.67 billion during the comparable 2020 period).



Costs Related to Early Extinguishment of Debt:





In connection with the refinancing transaction completed during the third
quarter of 2021, our results of operations for the three and nine-months ended
September 30, 2021 include a pre-tax charge of approximately $17 million
incurred for the costs related to the extinguishment of debt. This charge, which
is included in other (income) expense, net, consists of the write-off of
deferred charges (approximately $7 million) as well as the make-whole premium
paid on the early redemption of the $400 million, 5% senior notes (approximately
$10 million).


Provision for Income Taxes and Effective Tax Rates:

The effective tax rates, as calculated by dividing the provision for income taxes by income before income taxes, were as follows for the three and nine-month periods ended September 30, 2021 and 2020 (dollar amounts in thousands):



                                                  Three months ended                       Nine months ended
                                           September 30,       September 30,       September 30,       September 30,
                                               2021                2020                2021                2020
Provision for income taxes                $        67,515     $        79,172     $       232,844     $       204,649
Income before income taxes                        286,890             323,264             986,565             849,705
Effective tax rate                                   23.5 %              24.5 %              23.6 %              24.1 %


                                       55

--------------------------------------------------------------------------------




The provision for income taxes decreased $12 million during the three-month
period ended September 30, 2021, as compared to the third quarter of 2020, due
primarily to: (i) the income tax benefit recorded in connection with the $35
million decrease in pre-tax income, and; (ii) a $3 million decrease in the
provision for income taxes recorded in connection with ASU 2016-09.

The provision for income taxes increased $28 million during the nine-month
period ended September 30, 2021, as compared to the first nine months of 2020,
due primarily to: (i) the income tax provision recorded in connection with the
$145 million increase in pre-tax income, partially offset by; (ii) a $7 million
decrease in the provision for income taxes recorded in connection with ASU
2016-09.

Liquidity

Net cash provided by operating activities



Net cash provided by operating activities was $562 million during the nine-month
period ended September 30, 2021 and $2.218 billion during the first nine months
of 2020. The net decrease of $1.656 billion was attributable to the following:

• an unfavorable change of $1.576 billion resulting primarily from the early

return of the $695 million of Medicare accelerated payments which were

repaid during the first quarter of 2021, as compared to a favorable change

of $878 million experienced during the first nine months of 2020 resulting


      from receipt of the Medicare accelerated payments and other deferred
      governmental stimulus grants;

• a favorable change of $153 million resulting from an increase in net income


      plus depreciation and amortization expense, stock-based compensation
      expense, gain/loss on sale of assets and businesses, costs related to debt
      extinguishment and provision for asset impairment;

• an unfavorable change of $111 million due to the first nine months of 2020

including the favorable impact of the payment deferral of the employer's


      share of Social Security taxes, as provided for by the CARES, Act;


  • an unfavorable change of $75 million in accounts receivable;

• an unfavorable change of $51 million in accrued and deferred income taxes,


      and;


  • $4 million of other combined net favorable changes.


Days sales outstanding ("DSO"): Our DSO are calculated by dividing our net
revenue by the number of days in the nine-month periods. The result is divided
into the accounts receivable balance at September 30th of each year to obtain
the DSO. Our DSO were 51 days at both September 30, 2021 and 2020.

Net cash used in investing activities

During the first nine months of 2021, we used $660 million of net cash in investing activities as follows:

$666 million spent on capital expenditures including capital expenditures

for equipment, renovations and new projects at various existing facilities;

$39 million spent on acquisition of business and property;

$21 million received from the sale of our equity interest in a business;

$20 million received in connection with the implementation of information

technology applications (consists primarily of refunded costs previously

paid), and;

$4 million received in connection with net cash inflows from forward

exchange contracts that hedge our investment in the U.K. against movements

in exchange rates.

During the first nine months of 2020, we used $575 million of net cash in investing activities as follows:

$547 million spent on capital expenditures including capital expenditures

for equipment, renovations and new projects at various existing facilities;

$52 million spent on acquisition of businesses and property;

$22 million received in connection with net cash inflows from forward

exchange contracts that hedge our investment in the U.K. against movements


      in exchange rates;


  • $8 million received from the sale of assets and businesses;


   •  $5 million spent on the purchase and implementation of information
      technology applications, and;


  • $1 million spent on investments in joint ventures.


                                       56

--------------------------------------------------------------------------------

Net cash used in financing activities

During the first nine months of 2021, we used $936 million of net cash in financing activities as follows:

• spent $3.027 billion on net repayments of debt as follows: (i) $1.9 billion

related to our tranche A term loan facility; (ii) $490 million related to

our recently terminated tranche B term loan facility; (iii) $410 million

related to the early redemption of our previously outstanding $400 million,

5.00% senior secured notes which were scheduled to mature in June, 2026;

(iv) $225 million in connection with our accounts receivable securitization

program, and; (v) $2 million related to other debt facilities;

• generated $2.912 billion of additional borrowings as follows: (i) $1.7

billion related to our tranche A term loan facility; (ii) $699 million (net

of discount) related to the August, 2021 issuance of $700 million, 1.65%

senior secured notes due in September, 2026; (iii) $499 million (net of

discount) related to the August, 2021 issuance of $500 million, 2.65% senior


      secured notes due in January, 2032, and; (iv) received $14 million of
      proceeds related to other debt facilities;

• spent $770 million to repurchase shares of our Class B Common Stock in

connection with: (i) open market purchases pursuant to our stock repurchase

program ($751 million), and; (ii) income tax withholding obligations related

to stock-based compensation programs ($19 million);

• spent $50 million to pay cash dividends of $.20 per share during each of the

first, second and third quarters;

• spent $18 million to pay financing costs incurred in connection with the

various financing transactions, as discussed herein;

• received $13 million in connection with the sale of ownership interest to

minority members;

• generated $10 million from the issuance of shares of our Class B Common

Stock pursuant to the terms of employee stock purchase plans, and;

• spent $6 million to pay profit distributions related to noncontrolling

interests in majority owned businesses.

During the first nine months of 2020, we used $603 million of net cash in financing activities as follows:

• spent $1.174 billion on net repayments of debt as follows: (i) $700 million

to redeem our previously outstanding 4.75% senior secured notes which were

scheduled to mature in 2022; (ii) $400 million related to our accounts

receivable securitization program; (iii) $38 million related to our tranche

A term loan facility; (iv) $4 million related to our tranche B term loan

facility, and; (v) $32 million related to a short-term credit facility ($31

million) and other debt facilities ($1 million).

• generated $803 million of proceeds as follows: (i) $798 million of proceeds

(net of discount) received in connection with the issuance in September,

2020 of the $800 million, 2.65% senior secured notes which are scheduled to

mature in 2030, and; (ii) $5 million related to other debt facilities;

• spent $200 million to repurchase shares of our Class B Common Stock in

connection with: (i) open market purchases pursuant to our $2.7 billion

stock repurchase program, which has since been suspended as a result of the

COVID-19 pandemic ($197 million), and; (ii) income tax withholding

obligations related to stock-based compensation programs ($3 million);

• spent $15 million to pay profit distributions related to noncontrolling

interests in majority owned businesses;

• spent $17 million to pay cash dividends of $.20 per share during the first

quarter (prior to dividends being suspended from April, 2020 until March,


      2021 as a result of various initiatives implemented by us related to the
      COVID-19 pandemic);

• generated $9 million from the issuance of shares of our Class B Common Stock

pursuant to the terms of employee stock purchase plans;

• spent $8 million to pay financing costs incurred in connection with the $800

million, 2.65% senior secured notes which were issued during the third

quarter of 2020, and;

• spent $1 million to purchase ownership interest from minority members.

Expected capital expenditures during remainder of 2021



Our estimated capital expenditures for the full year of 2021 are projected to be
approximately $850 million to $1.0 billion. During the first nine months of
2021, we spent approximately $666 million on capital expenditures. During the
remaining three months of 2021, we expect to spend approximately $184 million to
$334 million which includes expenditures for capital equipment, renovations and
new projects at existing hospitals.

We believe that our capital expenditure program is adequate to expand, improve
and equip our existing hospitals. We expect to finance all capital expenditures
and acquisitions with internally generated funds and/or additional funds, as
discussed below.

                                       57

--------------------------------------------------------------------------------

Capital Resources

Cash and Cash Equivalents



As of September 30, 2021, we had approximately $190 million of cash and cash
equivalents consisting primarily of short-term cash accounts on which interest
is being earned at various annual rates ranging from 0.20% to 0.26%.

Credit Facilities and Outstanding Debt Securities



On August 24, 2021, we entered into a seventh amendment to our credit agreement
dated as of November 15, 2010, as amended and restated as of September 21, 2012,
August 7, 2014 and October 23, 2018, among UHS, as borrower, the several banks
and other financial institutions from time to time parties thereto, as lenders,
and JPMorgan Chase Bank, N.A., as administrative agent, (the "Credit
Agreement"). In September, 2021, we entered into an eight amendment to our
Credit Agreement which modified the definition of "Adjusted LIBO Rate".

The seventh amendment to the Credit Agreement, among other things, provided for the following:

o a $1.2 billion aggregate amount revolving credit facility, which is

scheduled to mature on August 24, 2026, representing an increase of $200

million over the $1.0 billion previous commitment. As of September 30, 2021,

this facility had no borrowings outstanding and $1.196 billion of available

borrowing capacity, net of $4 million of outstanding letters of credit;

o a $1.7 billion tranche A term loan facility, which is scheduled to mature on

August 24, 2026, resulting in a reduction of $150 million from the $1.85

billion of borrowings outstanding under the previous tranche A term loan


      facility, and;


   o  repayment of approximately $488 million of outstanding borrowings and
      termination of the previous tranche B term loan facility.


Pursuant to the terms of the seventh amendment, the tranche A term loan, which
had $1.70 billion of borrowings outstanding as of September 30, 2021, provides
for installment payments of $10.625 million per quarter beginning on December
31, 2021 through September 30, 2023 and $21.25 million per quarter beginning on
December 31, 2023 through June 30, 2026. The unpaid principal balance at June
30, 2026 is due on the maturity date.

Borrowings under the Credit Agreement bear interest at our election at either
(1) the ABR rate which is defined as the rate per annum equal to the greatest of
(a) the lender's prime rate, (b) the weighted average of the federal funds rate,
plus 0.5% and (c) one month LIBOR rate plus 1%, in each case, plus an applicable
margin based upon our consolidated leverage ratio at the end of each quarter
ranging from 0.25% to 0.625% for revolving credit and term loan A borrowings or
(2) the one, three or six month LIBOR rate (at our election), plus an applicable
margin based upon our consolidated leverage ratio at the end of each quarter
ranging from 1.25% to 1.625% for revolving credit and term loan A borrowings. As
of September 30, 2021, the applicable margins were 0.25% for ABR-based loans and
1.25% for LIBOR-based loans under the revolving credit and term loan A
facilities. The revolving credit facility includes a $125 million sub-limit for
letters of credit. The Credit Agreement is secured by certain assets of the
Company and our material subsidiaries (which generally excludes asset classes
such as substantially all of the patient-related accounts receivable of our
acute care hospitals, and certain real estate assets and assets held in
joint-ventures with third parties) and is guaranteed by our material
subsidiaries.

The Credit Agreement includes a material adverse change clause that must be
represented at each draw. The Credit Agreement also contains covenants that
include a limitation on sales of assets, mergers, change of ownership, liens and
indebtedness, transactions with affiliates, dividends and stock repurchases; and
requires compliance with financial covenants including maximum leverage. We are
in compliance with all required covenants as of September 30, 2021 and December
31, 2020.

On August 24, 2021, we completed the following via private offerings to
qualified institutional buyers under Rule 144A and to non-U.S. persons outside
the United States in reliance on Regulation S under the Securities Act of 1933,
as amended:

o Issued $700 million of aggregate principal amount of 1.65% senior secured

notes due on September 1, 2026, and;

o Issued $500 million of aggregate principal amount of 2.65% senior secured

notes due on January 15, 2032.




In April, 2021, our accounts receivable securitization program
("Securitization") was amended (the eighth amendment) to: (i) reduce the
aggregate borrowing commitments to $20 million (from $450 million previously);
(ii) slightly reduce the borrowing rates and commitment fee, and; (iii) extend
the maturity date to April 25, 2022 (from April, 2021 previously). Substantially
all other material terms and conditions remained unchanged. There were no
borrowings outstanding pursuant to the Securitization as of September 30, 2021.

On September 13, 2021, we redeemed $400 million of aggregate principal amount of
5.00% senior secured notes, that were scheduled to mature on June 1, 2026, at
102.50% of the aggregate principal, or $410 million.

As of September 30, 2021, we had combined aggregate principal of $2.0 billion from the following senior secured notes:

o $700 million aggregate principal amount of 1.65% senior secured notes due in

September, 2026 ("2026 Notes") which were issued on September 13, 2021.




                                       58

--------------------------------------------------------------------------------

o $800 million aggregate principal amount of 2.65% senior secured notes due in

October, 2030 ("2030 Notes") which were issued on September 21, 2020.

o $500 million of aggregate principal amount of 2.65% senior secured notes due

in January, 2032 ("2032 Notes") which were issued on September 13, 2021.

On September 28, 2020, we redeemed the entire $700 million aggregate principal amount of our previously outstanding 4.75% senior secured notes, which were scheduled to mature in August, 2022, at 100% of the aggregate principal amount.



Interest on the 2026 Notes is payable on March 1st and September 1st until the
maturity date of September 1, 2026. Interest on the 2030 Notes payable on April
15th and October 15th, until the maturity date of October 15, 2030. Interest on
the 2032 Notes is payable on January 15th and July 15th until the maturity date
of January 15, 2032.

The 2026 Notes, 2030 Notes and 2032 Notes (collectively "The Notes") were
offered only to qualified institutional buyers under Rule 144A and to non-U.S.
persons outside the United States in reliance on Regulation S under the
Securities Act of 1933, as amended (the "Securities Act"). The Notes have not
been registered under the Securities Act and may not be offered or sold in the
United States absent registration or an applicable exemption from registration
requirements.

The Notes are guaranteed (the "Guarantees") on a senior secured basis by all of
our existing and future direct and indirect subsidiaries (the "Subsidiary
Guarantors") that guarantee our Credit Agreement, or other first lien
obligations or any junior lien obligations.  The Notes and the Guarantees are
secured by first-priority liens, subject to permitted liens, on certain of the
Company's and the Subsidiary Guarantors' assets now owned or acquired in the
future by the Company or the Subsidiary Guarantors (other than real property,
accounts receivable sold pursuant to the Company's Existing Receivables Facility
(as defined in the Indenture pursuant to which The Notes were issued (the
"Indenture")), and certain other excluded assets). The Company's obligations
with respect to The Notes, the obligations of the Subsidiary Guarantors under
the Guarantees, and the performance of all of the Company's and the Subsidiary
Guarantors' other obligations under the Indenture, are secured equally and
ratably with the Company's and the Subsidiary Guarantors' obligations under the
Credit Agreement and The Notes by a perfected first-priority security interest,
subject to permitted liens, in the collateral owned by the Company and its
Subsidiary Guarantors, whether now owned or hereafter acquired. However, the
liens on the collateral securing The Notes and the Guarantees will be released
if: (i) The Notes have investment grade ratings; (ii) no default has occurred
and is continuing, and; (iii) the liens on the collateral securing all first
lien obligations (including the Credit Agreement and The Notes) and any junior
lien obligations are released or the collateral under the Credit Agreement, any
other first lien obligations and any junior lien obligations is released or no
longer required to be pledged. The liens on any collateral securing The Notes
and the Guarantees will also be released if the liens on that collateral
securing the Credit Agreement, other first lien obligations and any junior lien
obligations are released.

In connection with the issuance of The Notes, the Company, the Subsidiary
Guarantors and the representatives of the several initial purchasers, entered
into Registration Rights Agreements (the "Registration Rights Agreements"),
whereby the Company and the Subsidiary Guarantors have agreed, at their expense,
to use commercially reasonable best efforts to: (i) cause to be filed a
registration statement enabling the holders to exchange The Notes and the
Guarantees for registered senior secured notes issued by the Company and
guaranteed by the then Subsidiary Guarantors under the Indenture (the "Exchange
Securities"), containing terms identical to those of The Notes (except that the
Exchange Securities will not be subject to restrictions on transfer or to any
increase in annual interest rate for failure to comply with the Registration
Rights Agreements); (ii) cause the registration statement to become effective;
(iii) complete the exchange offer not later than 60 days after such effective
date and in any event on or prior to a target registration date of March 21,
2023 in the case of the 2030 Notes and February 24, 2024 in the case of the 2026
and 2032 Notes, and; (iv) file a shelf registration statement for the resale of
The Notes if the exchange offers cannot be effected within the time periods
listed above. The interest rate on The Notes will increase and additional
interest thereon will be payable if the Company does not comply with its
obligations under the Registration Rights Agreements.

At September 30, 2021, the carrying value and fair value of our debt were each
approximately $3.75 billion. At December 31, 2020, the carrying value and fair
value of our debt were each approximately $3.9 billion. The fair value of our
debt was computed based upon quotes received from financial institutions. We
consider these to be "level 2" in the fair value hierarchy as outlined in the
authoritative guidance for disclosures in connection with debt instruments.

Our total debt as a percentage of total capitalization was approximately 37% at September 30, 2021 and 38% at December 31, 2020.



We expect to finance all capital expenditures and acquisitions and pay dividends
and potentially repurchase shares of our common stock utilizing internally
generated and additional funds. Additional funds may be obtained through:
(i) borrowings under our existing revolving credit facility, which had $1.196
billion of available borrowing capacity as of September 30, 2021, or through
refinancing the existing Credit Agreement; (ii) the issuance of other short-term
and/or long-term debt, and/or; (iii) the issuance of equity. We believe that our
operating cash flows, cash and cash equivalents, available commitments under
existing agreements, as well as access to the capital markets, provide us with
sufficient capital resources to fund our operating, investing and financing
requirements for the next twelve months. However, in the event we need to access
the capital markets or other sources of financing, there can be no assurance
that we will be able to obtain financing on acceptable terms or within an
acceptable time. Our inability to obtain financing on terms acceptable to us
could have a material unfavorable impact on our results of operations, financial
condition and liquidity.

                                       59

--------------------------------------------------------------------------------

Off-Balance Sheet Arrangements



During the three months ended September 30, 2021, there have been no material
changes in the off-balance sheet arrangements consisting of standby letters of
credit and surety bonds.

As of September 30, 2021 we were party to certain off balance sheet arrangements
consisting of standby letters of credit and surety bonds which totaled $169
million consisting of: (i) $159 million related to our self-insurance programs,
and; (ii) $10 million of other debt and public utility guarantees.

© Edgar Online, source Glimpses